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Abstract 
Background  
It is unclear what is the true prevalence of HIV related acute pancreatitis and whether diagnostic and 
prognostic markers used in patients without HIV infection are as effective in HIV related pancreatitis 
and if morbidity is worse in HIV infected patients.  
Methods  
Using a prospective, descriptive design, HIV prevalence was compared in trauma and acute 
pancreatitis patients. Serum amylase was used to diagnose acute pancreatitis. Prognostication was 
by CRP, BISAP, Glasgow and APACHE II scores at 24 hours. Sensitivity, specificity and AUC were 
compared in predicting a severe outcome in acute pancreatitis. Complications and mortality were 
compared in 238 HIV+ve and HIV-ve patients admitted to 2 regional hospitals in Durban between 
August 2013 and October 2015. One hundred and eighty one patients were admitted with trauma.   
Results  
Between August 2013 and October 2015, 238 patients were admitted with acute pancreatitis and 181 
with trauma. HIV infection was higher in patients with acute pancreatitis (38% vs 16%) (p=0.001) 
and they were also older (40 vs 33 years) (p=0.001). Fifty three percent of HIV +ve patients were 
female and 65% of the HIV-ve patients were male in the pancreatitis cohort and 59% of the trauma 
and pancreatitis patients were on Highly Active Antiretroviral Therapy. The prevalence of gallstone 
(27% vs 30%), alcohol (41% vs 52%), dyslipidaemia (0% vs 3%) and idiopathic (6% vs 14%) 
aetiologies were similar in HIV+ve and HIV-ve patients and a drug related aetiology (24% vs 0%) 
(p<0.001) was more prevalent in HIV related acute pancreatitis.  
CRP was more effective in predicting severe disease in HIV-ve patients (AUC= 0.75) and patients 
with CD4 counts of ≥ 200 cells/mm3 (AUC=0.73) and not HIV+ve patients (AUC= 0.59) or patients 
with counts below 200 cells/mm3 (AUC= 0.46). The BISAP system had similar efficacy with AUC 
of 0,71 and 0.74 in HIV-ve and HIV+ve patients respectively, was poor in CD4 count < 200 
cells/mm3 (AUC=0.68) and good in CD4 count> 200 cells/mm3 (AUC=0.9). The Glasgow score was 
of similar efficacy in HIV-ve (AUC = 0.72) and HIV+ve patients (AUC=0.78) and better in patients 
with CD4 count < 200 cells/mm3 (AUC=0.83) and CD4 count ≥ 200 cells/mm3 (AUC=0.81). The 
 xiv  
APACHE II had uniform efficacy in both HIV-ve and HIV+ve patients (AUC >0.8) and both CD4 
count ranges (AUC > 0.80).  
Septic complications occurred in 10(8%) of HIV-ve patients and 4(4%) HIV+ve patients. There was 
no difference in morbidity (25% vs 33%) and mortality (6% vs 6%).  
          Conclusions  
HIV infections is more prevalent in acute pancreatitis than in a hospital trauma cohort which 
represented the general population.  The APACHE II system was the most accurate in predicting 
morbidity and CRP least accurate. The outcomes were similar in HIV+ve and HIV-ve patients but 
the statistical assumptions in calculating the sample size, given the low frequency of morbidity and 
mortality observed in this study may have resulted in an alpha error.   
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CHAPTER 1: INTRODUCTION   
 
1.1 Context 
Individuals afflicted with acute pancreatitis present with features of an acute abdomen. The diagnosis 
is established by differentiating the condition from other causes of the acute abdomen based on a 
combination of typical clinical symptoms (epigastric pain, nausea and vomiting) and pancreatic 
enzyme elevation 3 times or more than the upper limit of normal. The disease runs a variable clinical 
course from a mild self-limiting disease in most instances to a severe disease with organ failure and 
mortality. Predicting severe disease with organ failure aids in determining the need for intensive care 
support. It also facilitates comparison of outcomes between different centres and patient selection to 
compare established or novel therapies or interventions. Predicting a severe outcome is preferably done 
at presentation to enable closer monitoring for the development of organ failiure. The disease has a 
number of aetiological associations that are detailed in Table 1. The majority are associated with 
alcohol and gallstones but there is wide geographical variation in the frequency of these aetiologies 
that is summarised in Table 2 (2-19) that have implications for therapy. Reports that acute pancreatitis 
is associated with Human Immunodeficiency Virus (HIV) infection initially emanated from countries 
that had an HIV infection prevalence of under 1%. (1) The relationship between HIV and acute 
pancreatitis has not been fully elucidated but there are a number of factors to be considered.  
             1.1.1   Incidence of acute pancreatitis in HIV infection  
The aetiologies include those specifically related to HIV infection such as drug therapy, opportunistic 
infections and malignancies as well as the known causes of acute pancreatitis. Prior to the 
introduction of Highly Active Antiretroviral Therapy (HAART), clinical pancreatitis was 
demonstrated in 12(23.5%) of 51 patients but asymptomatic elevations of amylase and lipase were 
identified in 10 additional patients.(20) In the same era 14(32%) of 44 patients had raised amylase 
levels but only 7(16%) had acute pancreatitis. (21) These levels are higher than the 0.004.- 0.045 
percent of the general population who develop acute pancreatitis every year. (22)    
In data from the period prior to 1996, 22% of patients with AIDS developed pancreatitis whilst in the 
next decade which corresponds to the introduction of HAART, a reduced  incidence  of 14% has been 
reported.(23) In 2008 when HAART was well established across the globe an assessment of an Italian 
cohort of 1081 HIV-infected patients revealed prolonged laboratory enzyme abnormalities with signs 
of organ involvement in 15% of patients. (24) These three reports suggest a temporal fall in the 
prevalence in HIV infection related acute pancreatitis that has now stabilised. This aetiological 
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association between HIV infection and acute pancreatitis is highly pertinent to South African clinical 
practice with its 19.2% prevalence of HIV in the 15-49 year old population group. (25)   
In the setting of HIV infection the diagnosis of acute pancreatitis is complicated by several factors. 
Asymptomatic elevation of amylase and lipase in this population is common. (26, 27) This may be due 
to parotid disease, macroamylasemia or pancreatic disease. (27) There was no difference between 
patients with hyperamylasaemia and normoamylasaemia in terms of age, CD4 counts or medications. 
(27) Others have found hyperamylasemia more frequently in those with concomitant chronic hepatitis 
B or C infection, previous intravenous cotrimoxazole use, stage 2 HIV disease and intravenous drug 
use. (28) In a study of 1081 HIV infected individuals at least one episode of abnormal amylase levels 
was observed in 435(40.2%) individuals over a minimum follow-up of 12 months. (24) These patients 
had a longer duration of seropositivity, exposure to protease inhibitors, more frequently had Acquired 
Imune Deficiency Syndrome (AIDS), chronic liver or biliary disease and hypertriglyceridaemia. There 
was no relation between antiretroviral administration and the duration or type of nucleoside analogues, 
when compared with those with and without amylase elevations. In the same study prolonged amylase 
abnormalities developed in 166 (38.2%) patients and were related to the administration of antiretroviral 
medications, cotrimoxazole or antitubercular/antimycobacterial therapy, cytotoxic chemotherapy, 
illicit substance or alcohol abuse, opportunistic infections, chronic liver or biliary disease, a protease 
inhibitor-based HAART regimen and hypertriglyceridaemia. In 46 patients there were clinical signs or 
imaging evidence of pancreatitis and 120 were asymptomatic. (24)    
In a HIV study by Murthy, prior to the HAART era, 21 of 39 patients with AIDS had hyperamylasemia 
(2/3 pancreatic amylase, 1/3 salivary amylase) but only 6 patients had pancreatitis. (27) Biliary tract 
disease, alcohol intake and opportunistic infections were similar in those with normal and elevated 
amylase. Non-Caucasian race, pentamidine use and infection with mycobacterium avium-intracellulare 
were shown to be significant independent predictors of hyperamylasemia.(27) Fatal outcomes were 
also similar in those with and without hyperamylasemia.  The origin of hyperamylasaemia in this 
setting was not clarified. These abnormalities were not confined to serum amylase as Argiris found 
asymptomatic elevations of amylase and lipase in 52 of 86 HIV infected patients.(23) However, a 
minority 14% had elevations of greater than 2-fold the upper limit of normal. None of these patients 
had macroamylasemia and the majority were pancreatic in origin on isoenzyme testing. In this series 
elevated amylase and lipase were associated with symptomatic HIV infection, chronic hepatitis B or C 
infection, treatment with Pentamidine or intravenous Cotrimoxazole, Pneumocystis Carinii Pneumonia 
(PCP) infection and treatment with Zidovudine.   
Dutta found that in a total of 321 patients with HIV disease, 45(14%) patients developed at least one 
episode of acute pancreatitis as defined by clinical and laboratory criteria during a period of one year. 
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They demonstrated a significant correlation between CD4 counts and serum amylase levels, and 
asymptomatic elevation of amylase levels were reported in symptomatic HIV and AIDS patients but 
not in asymptomatic HIV infection.(28) The origin of hyperamylasaemia in this setting was also not 
clarified.  
Prior to HAART, histological assessment of the pancreas in post-mortem studies revealed that 10% of 
patients had significant pancreatic lesions caused by infection or tumours. (29) In a series of 
asymptomatic individuals the pancreas was infected by mycobacteriosis (22%), toxoplasmosis (13%), 
cytomegalovirus (9%) and pneumocystis carinii (9%) at post-mortem assessment. (30) Ultrasound and 
CT scan evaluation of the pancreas in HIV infected individuals also showed abnormalities in the 
pancreas which included local or diffuse enlargement, a dilated pancreatic duct, pseudocysts and 
abscesses. (31)  
The advent of HAART in 1996 resulted in prolonged HIV-1 viral remission with a decline in HIV 
virus-related complications and death. The management of HIV infection is focused on the suppression 
of the viral load and prevention of opportunistic infections.   
            1.1.2 Prevalence of HIV infection in Acute Pancreatitis in South Africa 
In South Africa we have observed an increase in the prevalence of HIV infection in patients presenting 
with acute pancreatitis from 5% in 2008 to 17% in 2017. (17, 19)  
1.1.3 Aetiology of acute pancreatitis in HIV Infection   
There have been attempts to set the causation criteria for drugs and infection in patients with 
pancreatitis but proving that HAART or other drugs for opportunistic infection prophylaxis are the 
cause of the pancreatitis remains difficult.  This is pertinent since the rate of pancreatitis in HIV+ve 
patients was higher prior to the advent of HAART. Six classes of antiretroviral agents currently exist. 
The Nucleoside Reverse Transcriptase Inhibitors (NRTIs) were the first agents available for the 
treatment of HIV Infection and Emtricitabine, Lamivudine(3TC) and Tenofovir (TDF) are used in 
treatment regimens in South Africa. They were associated with pancreatitis as a result of impaired 
cellular respiration and tissue damage. The Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs) commonly utilized in South Africa are Efavirenz and Nevirapine. Neurological symptoms, 
rash and hepatotoxicity are the main side effects in this group. The Protease Inhibitors (PI), Integrase 
Inhibitors, Fusion inhibitors and Chemokine Receptor Antagonists (CCR5) groups are not commonly 
utilised in the public hospitals in the Durban region.   
The criteria used to determine whether a drug is a likely cause of acute pancreatitis were described by 
Mallory and Kerr (32) and modified by Badalov.(33)(Annexure Table 1) When these criteria are 
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applied to medications commonly used in the treatment of HIV, the medications, and their assigned 
likelihood associated with acute pancreatitis are, in decreasing likelihood, Pentamidine(Ia), 
Didanosine(Ib), Lamivudine(Ib), Nelfinavir(Ib) and Ritonovir(IV).  Similarly among the antimicrobials 
commonly used in patients with HIV infection, Sulfamethoxazole(Ia), Isoniazid(Ia), Trimethoprim-
Sulfamethoxazole(Ib) and Rifampicin(IV) have been linked to acute pancreatitis. (33) These drugs are 
central to the management of these patients and there are no guidelines for altering drug regimens 
following an episode of acute pancreatitis where an alternate aetiology has been excluded. The 
management is individualized and takes into account the temporal relations between drug therapy and 
episodes of acute pancreatitis. Altering drug regimens may also compromise the primary goal of viral 
suppression. Opportunistic infections of the pancreas are common in post-mortem studies of these 
patients. A post-mortem pancreatic study in AIDS with normal antemortem ultrasound of the pancreas 
and normal serum amylase revealed mycobacteriosis (22%) and toxoplasmosis (13%) infection of the 
pancreas. There was no information on the diagnostic modalities appropriate for detecting these 
infections antemortem and therefore establishing them as a cause of acute pancreatitis is nigh 
impossible.(34,35) The evaluation of pancreatic infections is complicated by the relative inaccessibility 
of the pancreas and the risk of needling the pancreas that precludes routine sampling and culture. The 
criteria for ascribing a pathogen as a cause of acute pancreatitis is difficult to fulfil. Mild attacks with 
rapid resolution are unlikely to be investigated as additional therapy may be questioned. In addition, 
before an infective agent is assigned as the cause of acute pancreatitis other known aetiological 
associations must be excluded. In a symptomatic and biochemically diagnosed acute pancreatitis, the 
demonstration of the pathogen in pancreatic juice or blood, may make it permissible to attribute the 
cause to the microbe. (36)  
1.1.4 Severity grading in HIV related pancreatitis  
There is a paucity of information on whether the prognostic systems currently in use in grading acute 
pancreatitis are appropriate and effective in HIV associated pancreatitis. Dutta, in a retrospective 
review, using Ranson criteria demonstrated that 40% of their cohort were predicted to have mild disease 
and 60% moderate to severe disease. (28) The accuracy of the Ranson criteria in predicting adverse 
outcomes was not evaluated in this study by Dutta.    
Cappell demonstrated that the Ranson scale was a poor predictor (sensitivity 41%, PPV 53% and NPV 
52%) of outcomes and that the Acute Physiology And Chronic Health Evaluation 2nd edition (APACHE 
II) system had a sensitivity of 73% and a specificity of 68% in predicting a severe outcome in HIV+ve 
patients. The PPV and NPV were 70% and 71% respectively.(31) Gan demonstrated that the maximum 
accuracy was achieved with a cut-off of 14 for the APACHE II score and 4 for the Glasgow and Ranson 
criteria.(37) In contrast the best cut-off value in HIV-ve patients are markedly lower at 8, 3 and 3 for 
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the APACHE II, Glasgow and Ranson criteria respectively.(38-41) What is required is a prospective 
comparison of the accuracy of these scoring systems in predicting adverse outcomes in HIV+ve and 
HIV-ve patients with acute pancreatitis. 
1.1.5 Morbidity and mortality   
The outcomes in HIV related acute pancreatitis vary and Gan found that 15% of 73 patients with AIDS 
had severe disease as defined by ICU admission, death, local complications or surgical interventions, 
and seven patients (10%) died. (37) There was no differences in CD4 counts, AIDS status or years 
since diagnosis between mild and severe disease. They also found that the incidence of severe outcomes 
and mortality was comparable between their HIV +ve  patients and HIV-ve historical controls. (37) In 
a non-comparative observational study by Parithivel the mortality rate was reported as 32% in HIV+ve 
patients which is much higher than in reports on pancreatitis without HIV infection. (42)  
Factors influencing outcomes in patients with severe HIV associated pancreatitis are unclear. Afessa 
and Green from the University of Florida assessed 599 HIV +ve  patients admitted to ICU with critical 
illnesses and reported no difference in mortality between patients admitted with sepsis and patients 
admitted with Systemic Inflammatory Response Syndrome (SIRS) of a non-infectious aetiology. (43) 
They also observed that a low CD4 lymphocyte count was not associated with an increased mortality 
but noted that three of the four ICU admissions with acute pancreatitis died. (43) In another American 
study 17% of the patients with clinical pancreatitis died. (20) 
1.1.6 Summary  
Pancreatic enzyme elevations are common in HIV infected patients but clinical acute pancreatitis is 
lower. The use of total serum amylase in this population group may be unreliable as asymptomatic 
hyperamylasaemia is common and macroamylasaemia and the parotid fraction of total amylase have 
also been found to be elevated in HIV infected patients. The precise role of pancreatic isoamylase and 
lipase assays in this context are not defined. Despite this diagnostic dilemma, the prevalence of acute 
pancreatitis in HIV infected populations is higher than the general population. Although there has been 
a decline in HIV related pancreatitis after the introduction of HAART, there is a rising prevalence of 
HIV infection in pancreatitis cohorts in South Africa. In reports from regions with low HIV infection 
prevalence where alcohol and gallstones are responsible for the majority of cases of acute pancreatitis, 
the patients with HIV infection had AIDS, opportunistic infections and drugs as the more frequent 
causes of acute pancreatitis although alcohol and gallstone remained major aetiological considerations. 
There is thus a paucity of information on the spectrum of aetiologies of acute pancreatitis in areas with 
a high prevalence of HIV infection such as South Africa.   
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If pancreatitis occurs more frequently in the HIV infected community, then additional aetiological 
factors must exist which directly or indirectly enhance the susceptibility to acute pancreatitis. There 
are a large number of potential factors causing or associated with pancreatitis in HIV infected 
individuals and proving them as a cause of the disease is imprecise. This is pertinent since acute 
pancreatitis in HIV+ve patients was higher prior to the advent of HAART. This suggests the presence 
of additional causes of acute pancreatitis in HIV infection. 
1.2 Problem statement 
Despite this relevance there is a paucity of information on HIV and acute pancreatitis from South 
Africa. The few studies in a South African context have demonstrated an increase in the prevalence of 
HIV infection in patients presenting with acute pancreatitis. (17-19) (Table 2). These studies involved 
patients in whom HIV testing was not performed in all patients and are likely to have underestimated 
the prevalence of HIV infection in patients with acute pancreatitis.  
1.3 Hypotheses 
HIV infection is more prevalent in patients admitted with acute pancreatitis than in patients admitted 
as a result of trauma.  The prognostic systems used in non-HIV associated pancreatitis are not as 
effective in predicting the outcomes of pancreatitis associated with HIV infection. Acute pancreatitis 
associated with HIV infection results in a higher morbidity and mortality than in HIV negative patients.  
1.4 Research Objectives 
In the context of a high HIV prevalence environment, this study therefore sought to establish a bench 
mark data set and was conducted to 
1. Describe and compare the HIV prevalence in acute pancreatitis and trauma cohorts. The trauma 
cohort being representative of the general population 
2. Define and compare the applicability of diagnostic and severity assessment tools in HIV related 
pancreatitis. 
3. Determine and compare the morbidity and mortality rates in HIV+ve and HIV-ve patients with 
acute pancreatitis. 
4. Determine the factors associated with morbidity and mortality in HIV related pancreatitis. 
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 1.5 Methods and study period 
The study was a prospective descriptive analysis of acute pancreatitis and trauma cohorts over a two 
year period in two regional hospitals in the Durban region of Kwazulu Natal. 
1.6 Outline of study 
This chapter introduced the critical aspects of our current understanding of the association between 
HIV and acute pancreatitis and contexualised the research objectives. The literature review presents 
the current understanding of the diagnosis, severity assessment, aetiopathogenesis and treatment of 
acute pancreatitis. Secondly a synopsis of the epidemiology and other factors pertinent to HIV infection 
in South Africa is presented to detail aspects of the diagnosis, management and factors that influence 
morbidity and mortality. A brief description of the role of acute pancreatitis in mortality in HIV 
infection is presented. This sets the framework to formulate the study aim that is to address the paucity 
of critical analysis of the relationship between HIV infection and pancreatitis in an environment with 
a high prevalence of HIV infection. The thesis will be structrured as follows: 
Chapter 2 – Literature review  
Chapter 3 – Methodology and study design 
Chapter 4 – Results 
Chapter 5 – Discussion 
Chapter 6 – Synthesis and conclusion 
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Chapter 2: Literature review 
Section 1: Acute pancreatitis 
2.1 Clinical presentation and initial diagnosis  
Acute pancreatitis is a symptom complex consisting of severe persistent epigastric pain which may be 
associated with nausea and vomiting and radiates to the back. The physical examination may be 
unrevealing in mild attacks, whilst in those with severe disease signs of peritonitis are overt and 
respiratory distress and hypotension are often present. The condition is usually associated with an 
elevated serum amylase or lipase. These symptoms and biochemical combination suffice to arrive at a 
diagnosis in most cases. The clinical and biochemical criteria are not specific for acute pancreatitis and 
other diseases such as perforated duodenal ulcer, mesenteric ischaemia and bowel obstruction can also 
produce enzyme elevation. In instances of diagnostic doubt CT imaging is required to confirm acute 
pancreatitis or evaluate for other disease processes.(44) Emergency laparotomy may be performed 
when doubt persists and pancreatitis is diagnosed by fat saponification and inflammation of the gland.      
 
2.2 Enzyme elevation in the diagnosis of acute pancreatitis  
Table 3 provides a summary of a number of studies investigating the diagnostic accuracy of amylase 
and lipase which are the routinely used diagnostic tests. (45-54) These tests have been more commonly 
assessed than others and most studies show lipase to be the most accurate diagnostic test. However, 
investigations into amylase and lipase as diagnostic aids have not been standardized. Table 3 highlights 
the variation, in the analytic tests (including their isoenzyme fractions), their timing and cut-off values 
that make inter-study comparisons difficult.    
α-Amylase is an important enzyme within the gastrointestinal tract. The main sources are the salivary 
gland(S-type) and the pancreas(P-type) and the untyped lesser amylase activity that is found within the 
small bowel, lung and skeletal muscle. The usefulness of amylase in the diagnosis of acute pancreatitis 
was first demonstrated in 1929. (55) Following the initial insult, the serum amylase level increases 
rapidly over 3 to 6 hours. With a half-life of 10-12 hours, it can remain elevated for 3 to 5 days, but 
may be normal with background chronic pancreatitis, when hypertriglyceridaemia is present and with 
delayed presentations. It is excreted by the kidneys and may be falsely elevated in renal impairment.   
Serum lipase is composed of 3 subtypes which have pancreatic, hepatic and lipoprotein components 
with the pancreatic proportion being less than the lipoprotein and hepatic components when measured 
in asymptomatic subjects. (54) Serum lipase level increases in 3 to 6 hours and peaks in 24 hours. It is 
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more useful than amylase in delayed presentation since it can remain elevated for one to two weeks as 
it is reabsorbed by the kidney tubules. (56) The ratio of pancreatic lipase to total lipase subtypes was 
more accurate than pancreatic lipase and amylase in confirming pancreatitis diagnosed by contrast 
enhanced computed tomography scan at presentation. (54) (Table 3)  
Lipase was shown to be superior to amylase as it was found to be more sensitive and specific in an 
institution where both tests were available. (57) The authors found that the use of lipase alone was more 
cost effective than using both tests for pancreatitis. Elevations in amylase and lipase greater than 3 
times the upper limit of normal are uncommon in abdominal pain that is caused by extra-pancreatic 
diseases although a study by Hendry et al in 1987 found that 30(7%) of patients admitted with amylase 
levels above 1000IU/l had other abdominal conditions. (58) Ruptured aortic aneurysm, perforated 
duodenal ulcer, cholecystitis and intestinal obstruction were the other conditions that resulted in a 
markedly elevated amylase.  
Table 4 summarises the less frequently investigated diagnostic tests and again illustrates the varying 
levels of sensitivity and specificity calculated at different cut-off values. (45-49, 51) As with amylase 
and lipase standardization of these tests was poor, some were measured in serum and urine without 
stipulating which sampling route was considered the most worthwhile and the laboratory upper limits 
of normal values were not provided in some instances. Currently these tests have no clinical utility over 
amylase or lipase and are not used in routine practice.    
Despite alternatives amylase and lipase remain the most commonly used diagnostic biochemical 
markers because they are widely available and cost effective. Lipase has been evaluated to be superior 
to amylase in a number of studies and should be the preferred test. In resource constrained environments 
amylase is more widely available with assays of lipase performed offsite and delaying the diagnosis. 
However, clinicians should be aware that significant elevations in amylase may result from other 
medical conditions. CT imaging is required when pancreatic enzymes are normal or insignificantly 
elevated and if there is diagnostic doubt. On occasions when imaging is non-specific a laparotomy may 
be required as most alternative diseases which mimic acute pancreatitis are addressed by emergency 
surgery.   
 
2.3 Aetiology and epidemiology   
There has been an increase in hospital admissions for acute pancreatitis in European, American and Far 
Eastern settings (59, 60) with gender distribution dependent on aetiology and a mean age of 54-60 
years. (2, 9, 57) In South Africa there are no population based figures on the incidence of acute 
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pancreatitis and in hospital prevalence rates, acute pancreatitis represented 1% and 1.2% of all 
admissions to a general surgery service in two hospital populations. (15, 17)    
In most settings alcohol and gallstones are associated with 80% of cases of acute pancreatitis (Table 
2). In South Africa alcohol has been the aetiological association in 63-83% and gallstones in 7-14% of 
patients with acute pancreatitis. In studies from other centres in the world alcohol has been the cause 
in 7-33% and gallstones in 33-69% (Table 2). Alcohol causes a direct toxic effect on the pancreas and 
gallstone migration and transient obstruction of the ampulla with bile reflux into the pancreatic duct 
are thought to be the mechanisms of these aetiologies. Gallstone pancreatitis is more prevalent in 
females (61) with small gallstones(<5mm). Gallstone-related pancreatitis increases with age and peaks 
after 60 years of age whereas an alcohol cause peaks at 45 to 55 years and declines thereafter. (22)   
The concept of spasm of the sphincter of Oddi(SOD) as a mechanism of inducing acute pancreatitis 
was demonstrated in animal experiments. (62) The same authors suggested that recurrent pancreatitis 
after cholecystectomy in some patients could be attributed to spasm of the sphincter of Oddi. The SOD 
has three variants with types 1 and 11 associated with biliary dilatation and deranged liver function 
tests and the type 111 variant with abdominal pain. However longterm results of the of the endoscopic 
sphincterotomy for  SOD have shown that sphincterotomy does not result in pain improvement from 
the type 111 variant of  SOD dysfunction despite manometry revealing raised sphincter pressures.(63)     
In studies by Fortson and Cameron the association between hypertriglyceridaemia and pancreatitis was 
investigated. Caucasians and African Americans accounted for the majority of patients with 
hypertriglyceridaemia and pancreatitis. (64, 65)  Hypertriglyceridaemia in South Africa has an ethnic 
bias and is more frequently found in Caucasian and Indian racio-ethnic groups, is intermediate in those 
of mixed ethnicity and low in the indigenous African population. (66, 67) Pancreatitis associated with 
hypertriglyceridaemia was predominantly found in the Indian racio-ethnic group and was low in 
indigenous Africans. (66) Thirty-four percent of the admissions with acute pancreatitis in a Durban 
hospital had dyslipidaemia associated with pancreatitis over a 4-year period which is similar to the 
frequency in the series by Cameron and Buch who similarly performed routine testing for 
dyslipidaemia. (65, 66, 68) However only 26 (6%) had hypertriglyceridaemia greater than 10mmol/l in 
the Durban evaluation. (66)  
Primary hyperparathyroidism may be sporadic or familial and may exist alone or in combination with 
other endocrine disorders. The pathology may be glandular hyperplasia or an adenoma which causes 
increased levels of parathyroid hormone and an elevated serum calcium. Acute pancreatitis is a rare 
complication of hypercalcaemia caused by primary hyperparathyroidism occurring in 2% of patients 
with primary hyperparathyroidism. (69) In a cohort of patients with primary hyperparathyroidism, 
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pancreatitis was found in 3.2% of patients with a spectrum of acute and chronic forms of the disease. 
Calcium levels were higher in patients with pancreatitis than in those without pancreatitis. (70)  
Certain genetic disorders are associated with an increased susceptibility to acute pancreatitis. These 
include cationic trypsinogen (PRSS1), anionic trypsinogen (PRSS2), serine protease inhibitor Kazal 
1(SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), chymotrypsinogen 
C(CTRC) and calcium-sensing receptor (CASR). Patients with these genes are more prone to develop 
pancreatitis when exposed to causes of acute pancreatitis. PRSS1, PRSS2 and SPINK1 are genes which 
result in the premature activation of Trypsinogen whereas CFTR, CTRC and CASR resulted in altered 
ductal bicarbonate levels, susceptibility to trypsin and altered calcium metabolism which increased the 
prevalence of acute pancreatitis in subjects with these mutations (76)  
Congenital pancreatic anatomical variations (Pancreas divisum and annular pancreas) and malignant 
disease of the pancreas may cause acute pancreatitis. Pancreas divisum has been found in 16%, 16%, 
and 47% in those with idiopathic, and PRSS1, SPINK1, and CFTR mutation associated pancreatitis, 
suggesting that it is associted with gene mutations that cause acute pancreatitis and not a cause of the 
acute pancreatitis. (71)  
 In a Norwegian study 3% of acute pancreatitis was related to tumours and most of these patients 
presented with mild pancreatitis. The tumours were diagnosed at initial presentation or over a varying 
period thereafter. (72) In HIV associated pancreatitis 6(6%) of patients had associated cancers. (19) 
Hyperamylasaemia has also be associated with non-pancreatic malignancies. (73-75)  These tumours 
included an ovarian tumour, paraganglioma and multiple myeloma.  
Autoimmune pancreatitis is an uncommon cause of acute pancreatitis. The condition is due to 
autoantibodies cause acinar cells inflammation that usually responds to steriod therapy. It has type 1 
and type 2 variants, the former being associated with raised levels Immunoglobulin 4 (IgG4) and often 
present with obstructive jaundice and the latter without raised levels of IgG4 and most often presenting  
abdominal pain. (77) Type 1 is also associated with other autoimmune conditions and type 2 has an  
association with inflammatory bowel disease  
 
2.4 Determinants of Aetiology: biochemical and imaging   
 A variety of biochemical markers have been studied in relation to their ability to differentiate the 
various aetiologies to enable early interventions to prevent recurrent disease. Although there are no 
specific early interventions for an alcohol aetiology it is important to determine a gallstone cause of the 
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pancreatitis early in the disease as there are specific measures which may moderate the outcomes and 
prevent recurrent episodes. Although, the elevations of serum amylase and lipase are significantly 
lower in patients with alcoholic pancreatitis than in those with biliary pancreatitis, serum amylase and 
lipase concentrations do not establish the aetiology accurately. Studies have evaluated a variety of 
parameters against a gold standard to determine their accuracy in determining a gallstone aetiology.  
They are shown in (Table 5) (19, 57, 78-85) which illustrates the different and often multiple ‘gold 
standards’ used, the variability in the assays, their cut off levels and the temporal relationship of their 
measurement to the onset of symptoms. This makes comparison of these studies less than ideal. In 
South Africa with a low prevalence of gallstone related pancreatitis serum amylase > 1000IU/L was a 
predictor of biliary pancreatitis in female patients. (18) A biliary aetiology is associated with female 
gender in most assessments and was demonstrated to have a pre-test probability of 0.47 in females and  
0.06 in males. (18) The serum lipase-amylase ratio is also unhelpful in aetiological differentiation as 
the ratio for alcoholic, biliary and non-biliary and non-alcoholic pancreatitis was 0.2-5.6, 0.1-7.9 and 
0.1-4.4 respectively. (86) In studies which examined bilirubin, alkaline phosphatase, , a 3-fold elevation 
of ALT was associated with a 95% probability of gallstones as a cause of pancreatitis. (87) This was 
not improved by the use of  other liver enzymes alone or in combination with ALT(Table 5).The 
performance of the transaminases in predicting a biliary cause may depend on the timing of the assay 
in relation to the onset of symptoms as ALT within 24 hours had a sensitivity, specificity and positive 
predictive value of 73%, 86% and 92% respectively which were significantly higher than the values of 
these parameters at 72 hours. However, the latter remained a valuable predictor of a biliary cause. (88)   
Endoscopic ultrasound (EUS) and Magnetic Resonance Cholangiography (MRC) appear to be superior 
for determining a biliary aetiology (Table 5) but are usually used when there is diagnostic doubt of a 
biliary aetiology. EUS has a sensitivity of 94% - 100% and specificity of 95%-100% (89, 90) and MRC 
a sensitivity of 92-95% and specificity of 96%-99%. (91, 92) 
They are of limited use as they are not available to most patients at initial presentation particularly in 
less developed environments and gender, biochemical parameters and transabdominal ultrasound 
remain the most widely available predictors of a biliary origin.   
              
             2.5 Summary  
There exists a regional variation in the aetiological profile of acute pancreatitis but the majority of cases 
are related to alcohol and gallstones. In developed environments most pancreatitis is associated with 
gallstones whereas in South Africa the majority are associated with alcohol. Female gender is 
associated with a gallstone aetiology in all settings. In regions with a low prevalence of biliary 
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pancreatitis such as South Africa serum amylase is a predictor of a gallstone aetiology and ALT is a 
reliable predictor in all environments. Determining a gallstone aetiology is important as 
cholecystectomy and Endoscopic Retrograde CholangioPancreatography  (ERCP) and sphincterotomy 
reduce the risk of subsequent attacks. There are a number of other possible causes and these may have 
an ethnic or regional association as demonstrated by pancreatitis associated with hypertriglyceridaemia 
where there was an ethnic bias in a study from Durban. In a low HIV prevalence environment tumours 
have also been associated with acute pancreatitis. This association was more frequent in a high HIV 
prevalent environment.  The association between drugs and acute pancreatitis is determined by the 
temporal relationship between drug administration and acute pancreatitis and a number of drugs have 
been implicated.  Sphincter of Oddi dysfunction is usually detected when investigating idiopathic 
pancreatitis.  
2.6 Pathogenesis/Pathophysiology   
            2.6.1 Early events in the pancreas  
Experimental pancreatitis has provided insight into the early events in acute pancreatitis. (93) The 
autodigestion theory of pancreatitis is the oldest explanation for these events. Trypsinogen and other 
digestive enzymes secreted by the exocrine pancreas are inactive proenzymes during their synthesis, 
storage and secretion into the pancreatic duct. The secretion of proenzymes by the acinar cells through 
exocytosis is influenced by calcium signalling pathways. Activation of proenzymes normally occurs in 
the small intestines by enterokinases in the mucosal brush border. At the cellular level, animal models 
of pancreatitis have shown that co-localization of hydrolases and zymogen granules occurs and result 
in the activation of digestive enzymes intracellularly which leads to autodigestion. The activation of G 
protein-linked receptors is followed by increased levels of Inositol 1.4.5 – triphosphatase, nicotinic 
acid, adenine dinucleotide phosphatase (ADP) and cyclic ADP-ribose. This results in calcium release 
from the endoplasmic reticulum and an increase in the cytosolic calcium. This elevated calcium induces 
intracellular activation of digestive enzymes. (94) Due to premature activation of trypsinogen and other 
digestive enzymes the pancreas becomes inflamed and at times this process progresses to necrosis. This 
results in extracellular events within the pancreas and systemic activation of the inflammatory response 
with deleterious effects on organ function. The prototype of this process is hereditary pancreatitis, 
where mutations in the cationic trypsinogen gene result in premature trypsinogen activation and 
autodigestion.  
Experimental intra-acinar production of active trypsin has been shown to result in acinar death and 
local and systemic inflammation. (95)    
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Recent investigations have questioned the central and sole role of the autodigestion model. It has been 
demonstrated in experimental pancreatitis that the lack of trypsinogen does prevent pancreatic necrosis 
but does not inhibit the local and systemic inflammatory response. (96) Activation of trypsinogen takes 
place in membrane bound compartments when the zymogen and lysosomes co-localize with Cathepsin 
B activating trypsinogen in these vacuoles. In experimental pancreatitis where subjects were depleted 
of Cathepsin B or trypsinogen, local and systemic inflammation was found but with reduced pancreatic 
injury. This suggested that Trypsinogen activation was not necessary to induce acute pancreatitis and 
that  activation of NF-kB, which parallels the trypsinogen activation is a proven alternate pathway to 
pancreatic inflammation.  (97) 
The initiating event produces changes within the acinar cells. This results in local and systemic effects 
of variable degree. The natural history is either a mild self-limiting course or a severe disease with 
organ failure in 20% of patients. (98)  It would appear from these recent findings that Trypsinogen 
activation is an important but not the sole pathway in acute pancreatitis.   
             2.6.2 Gut mucosal dysfunction  
In severe acute pancreatitis, retroperitoneal inflammation results in third space loss and relative 
hypovolaemia. Activation of the sympathetic nervous system and the renin-angiotensin pathway results 
in vasoconstriction of the mesenteric postcapillary venules and the afferent arterioles. This augments 
the systemic blood pressure at the expense of the splanchnic bed. This results in impaired gut perfusion 
and loss of gut barrier function. (99) The integrity of the gut barrier is also compromised by the lack of 
nutrients in severe cases. The ensuing microbial translocation causes activation of immune cells and 
the release of inflammatory mediators which is thought to drive the systemic inflammatory response 
and multiple organ dysfunction syndrome. (99) This increased intestinal permeability has been 
demonstrated in patients with severe forms of acute pancreatitis. Intestinal permeability was also 
greater in patients with severe disease who developed multiple organ failure or died. (100)   
             2.6.3 Inflammatory response in acute pancreatitis  
The cytokine cascade which is initiated by the acinar cell damage is illustrated in Figure 1. This cascade 
illustrates the response in patients without HIV infection. A similar analysis has not been performed in 
HIV associated pancreatitis. Activation of leukocytes is key in the onset and propagation of the initial 
events associated with acute pancreatitis. (101) Cytokine and non-cytokine inflammatory mediators are 
raised in acute pancreatitis irrespective of the aetiology. (102) Interleukin (IL)-6, IL-8 and IL-10 peak 
early in acute pancreatitis(days 0-2) with significantly higher levels in severe disease. The response 
was also more sustained in cases of severe disease. (103)  Acute pancreatitis alters the plasma 
concentrations of acute phase proteins [C - reactive protein (CRP), alpha-1 antitrypsin, transferrin] 
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whose plasma concentrations may increase or decrease in response to cytokines.  A difference was 
found between gallstone and alcohol related pancreatitis in the levels of IL-8, but not in IL-6, IL-18, 
Tumour Necrosis Factor (TNF) -α and CRP.(65) Because plasma cytokines have short half-lives, 
quantification for clinical use is difficult and CRP is traditionally used as the measure of the acute phase 
response. The cytokine profiles associated with the cellular and humoral immunity are illustrated in 
Figure 1.  
2.7  Classification    
The first symposium on pancreatitis held in Marseille in 1963 defined 4 categories of pancreatitis 
namely acute pancreatitis, acute relapsing, chronic relapsing and chronic pancreatitis. (104) In 1984 
the Cambridge international gathering revised this to 2 categories of acute and chronic. (105) The 
Atlanta conference in 1992 distinguished acute pancreatitis as a separate entity with mild or severe 
categories. The predictors of severe disease, the definitions of organ failure and local complications 
were defined by consensus. (106) A review of subsequent publications and a comparison with the 
Atlanta criteria revealed a discordance in the diagnostic criteria, definitions of organ failure and the 
cut-off values in the prediction of severe disease. This resulted in a review of the classification and an 
international consensus based re-classification in 2012. (44) During these periods, the CT criteria for 
local complications have also undergone a number of changes since their original classification by the 
Atlanta consensus. (107) The most recent consensus meeting/statement on acute pancreatitis in 2012 
defined the diagnostic criteria, the predictors of severe disease and the role of organ failure, as defined 
by the Modified Marshall score, on outcomes (Table 6). Acute pancreatitis was classified into mild, 
moderate and severe forms and the CT scan criteria of local complications were defined. 
(44)(Annexure Table 2)  
  
2.8 Predicting Severity 
The need to prognosticate in acute pancreatitis arose from variable outcomes with about 25% of patients 
developing a complicated course which may be fatal. Predicting a severe outcome aids in determining 
the need for intensive monitoring and organ support, allows comparison of outcomes between different 
centres and provides endpoints for comparing established or novel therapies/interventions. Predicting 
a severe outcome is preferably done at presentation to enable early intervention and the ideal system 
for prognostication in acute pancreatitis should be available to medical personnel at various levels of 
care. It should be rapidly computed, inexpensive, compatible with district hospitals and available early 
in the course of the disease preferably in the first 24-hour period.  
 16  
             2.8.1 History and general factors in prognostication   
Prior to the 1970s, the assessment of severity was by clinical means. Clinical parameters such as 
tachycardia, respiratory distress, shock and signs of peritonitis are compatible with severe disease. In 
western environments old age has been associated with increased mortality. These clinical criteria 
predicted severe disease in 39% of patients with a severe attack. (108) Bruising and purple discoloration 
in the flanks, Grey Turner's sign, or periumbilical ecchymosis, Cullen’s sign, did predict a severe attack 
of acute pancreatitis but took 24–48 hours to develop and were seldom present. (109)  
             2.8.2 Age  
Advanced age has been a determinant of poorer outcome and is a factor in a number of prognostic 
systems. This is based on several studies analysing age alone as a predictor of mortality. A Scottish 
study by McKay reported on 19633 admissions of 13727 patients with acute pancreatitis between 
January 1984 and December 1995. The median age was 54 years and the authors demonstrated that 
mortality was 1-2% in those younger  than 40 years and more than 18% in those older than 70 years 
with 59% deaths occurring  in those older  than 70 years (Table 7). (110) In a study from England in 
1985 which examined 650 patients, the mean age at presentation was 60 years with a mortality rate of 
20%. Age was a predictor of death with a mortality of 28% in those older than 60 years and 9% in those 
below that age. (111) Frey in 2006 reported on 70231 patients with acute pancreatitis. (12) They 
showed a 15-fold and 22-fold greater chance of dying within 2 weeks and within 91 days respectively 
if the age was greater than 75 years. Advancing age in Western series is a consistent predictor of 
outcome and justifiably a component of systems that predict poor outcome.  
 2.8.3 Nutritional status as a predictor of outcome in acute pancreatitis  
The proportion of adults who are overweight or obese was 37% for men and 38% for women worldwide 
in 2013.(112) Obesity is defined by a BMI (body mass index of greater than 30) and is one of the 
clinical parameters that predicts a severe course of acute pancreatitis. Though lower than this 
worldwide average the prevalence of obesity in patients with acute pancreatitis is high and was 
demonstrated to be 28.9% in a Korean study and 21% and 24% in South African and Spanish cohorts. 
(16, 113, 114) These studies demonstrated that obesity was associated with more complications of 
acute pancreatitis. In a South African study, the mean(±SD) BMI of patients with severe acute 
pancreatitis was significantly higher than that in patients with mild disease 31.2(±5.6) versus 23.3(±5.6) 
kg/m2. In patients with a BMI>30, disease severity, abscess formation and mortality were demonstrated 
to be significantly higher. (16)   
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The addition of obesity (BMI>30) to the APACHE II score predicted severe acute pancreatitis with a 
sensitivity of 82%, specificity of 86%, positive predictive and negative predictive values of 74% and 
91% respectively. (115) However, in an American study in 2006 the admission APACHE O [Area 
Under the Curve (AUC) 0.895] and APACHE II (AUC 0.893) demonstrated similar accuracy in 
predicting a severe outcome although BMI > 30 was identified as a significant risk for severe acute 
pancreatitis and mortality. The CRP levels and Ranson score were also significantly higher in obese 
patients. (116)   
Further evidence was provided by Martinez in a meta-analysis of 739 patients where severe acute 
pancreatitis was significantly more frequent in obese patients (OR 2.9, 95% CI 1.8-4.6). (117) Obese 
patients also developed significantly more systemic (OR 2.3, 95% CI 1.4-3.8) and even more local 
complications (OR 3.8, 95% CI 2.4-6.6). The mortality rate was also higher in obese patients (OR 2.1, 
95% CI 1.0-4.8)   
             2.8.4 Peritoneal lavage  
Peritoneal lavage was superior to clinical assessment and equivalent to the Glasgow criteria in 
predicting a severe form of pancreatitis with sensitivities of 53%, 34% and 61% respectively. Visceral 
injury occurred in 2 of 253 patients (0.8%). (118) This method of prognostication has been discarded 
because of its invasive nature and the potential for visceral injury.  
             2.8.5 Multiple factor, single factor and radiological prognostication systems    
Subsequent prognosticators were developed within specific populations usually from high income 
countries with variable patient demographics aetiological mixes and comorbidities. In this regard a 
number of single factor and multifactorial scoring systems have been developed. Table 8 depicts 
accuracy metrics for a number of severity prediction factors in relation to their temporal use. (38-41, 
119-127) The various scoring systems have been utilized over a varying period after onset of symptoms 
and they have shown varying sensitivities and specificities in determining a severe outcome. The 
APACHE II system has been shown in several comparisons to be the most reliable of these tools.   
 
2.8.6 Multiple factor prognosticators   
In 1970 Ranson developed the first of the multifactorial scoring systems. (128) The APACHE II (129) 
and the Glasgow (Annexure Tables 3 and 4) (130) joined Ranson as the most commonly used scoring 
systems. The Ranson and Glasgow criteria are collated over 48 hours and are not suitable for early 
evaluation. The Ranson criteria were developed in a cohort of acute pancreatitis with alcohol as a cause 
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in 75% of patients and modifications to accommodate a biliary origin were impractical as the 
aetiological association was frequently unknown at the initial assessment. The APACHE system was 
initially developed and validated in the classification of patients in intensive care units where it proved 
to be reliable in predicting outcomes. (131) This system made allowance for the weighting of 34 
different physiological measures on a scale of 1 to 4. These provided a physiological score. The 
APACHE II score was a modification which reduced the physiological variables from 34 to 12 to 
simplify the score but added a premorbid assessment. (129, 132) The APACHE II score was found to 
discriminate between uncomplicated, complicated and fatal forms of acute pancreatitis. It was also of 
value in ongoing assessment as it revealed a worsening score in patients dying within 4 days and 
declining scores during the first seven days in those who survived the attack. (133) The APACHE III 
and later APACHE IV modifications used additional variables, expanded the disease codes to forty and 
remodelled the weighting of the different variables. This resulted in a possible range of scores of 0 to 
299 in the APACHE III. The APACHE IV score was calculated using 129 variables and in a study of 
266 patients with severe pancreatitis, an APACHE IV score of 44 or more predicted mortality in the 
15(5.6%) who died. (134) The receiver operating characteristic curve for APACHE IV was 0.93 (CI, 
0.88-0.97); APACHE II, 0.87 (CI, 0.80-0.94); Bedside Index for Severity in Acute Pancreatitis 
(BISAP), 0.86 (CI, 0.78-0.94); and Ranson criterion, 0.90 (CI, 0.94-0.96). These scores resulted in 
more complex calculations which were unsuitable for the primary assessment at initial presentation and 
was counter to trends which sought simpler prognosticators early in the disease process. In a study, 
further mitigating against their routine use, which compared the Ranson, APACHE II and APACHE 
III in 153 patients with acute pancreatitis, the Ranson criteria were equivalent to the APACHE II scores 
when there was a 24 - hour delay in the assessment of patients. The APACHE II and APACHE III 
scores had the same predictive value. (134)  
BISAP is a 5-point system based on one point for each of the following parameters: Urea, Impaired 
mental status, Systemic Inflammatory Response Syndrome (SIRS), age and pleural effusion as detailed. 
(Annexure Table 5)(135)  It was derived from data collected from 17,992 cases of acute pancreatitis 
from 212 hospitals in 2000-2001 and validated on data collected from 18,256 AP cases from 177 
hospitals in 2004-2005. (35) The ‘AUC’ of BISAP was 0.82 and 0.83 for the APACHE II system. 
Subsequently the BISAP score has been compared to other scoring systems in differing communities. 
A comparison of Ranson, BISAP, APACHE II, Computerized Tomography Severity Index (CTSI) and 
CRP at 24 hours in predicting severe disease revealed that the APACHE II score had the highest 
accuracy with an area under the curve of 0.78(95% CI: 0.7-0.84) without a statistically significant 
difference between the scoring systems. () The BISAP score was also found to be similar to the 
APACHE II and Ranson scoring systems in predicting a severe outcome in a Chinese population of 
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497 patients. (135) The BISAP scoring system has the advantage of simplicity and use within 24 hours 
of presentation.  
In HIV related pancreatitis there is limited evidence on the suitability of established prognostic systems. 
In a study by Gan, the APACHE II criteria best predicted outcome with an overall accuracy of 75% 
(Glasgow 69%, Ranson 48%). (37) In HIV related pancreatitis, maximal accuracy was achieved with 
cut-offs of 14 for APACHE II and 4 for the Glasgow and Ranson criteria.  
A severe outcome is associated with a severe inflammatory cascade which results in systemic organ 
dysfunction and mortality. The criteria for a SIRS have  been validated in large studies and include any 
2 of the predefined cut-offs of the following criteria: temperature, heart rate, respiratory, arterial partial 
pressure of carbon dioxide and white cell count (Annexure Table 6). (103) Since cytokine assays are 
not readily available and difficult to measure because of their brief half-lives, these systemic criteria 
are surrogates of the cytokine response. A persistent SIRS response at 48 hours is associated with 
persistent organ dysfunction and mortality. (136)  
Besides these scoring systems, there are others which have shown promise without wider validation. 
For example, the  score based on specific cut-offs has been demonstrated to be equivalent to Ranson, 
Glasgow and APACHE II systems in predicting mortality. (137, 138)  
 
2.8.7 The single factors prognosticators  
An Erythrocyte Sedimentation Rate (ESR) value of 60mm/hr or greater had a sensitivity and specificity 
of 86% and 57% at 36 hours while a CRP value of 150mg/L or greater at 36 hours had a sensitivity and 
specificity of 86% and 87% in predicting severe acute pancreatitis. A 36-hour delay to predicting 
severity is inadequate for early triage and the institution of early organ support. When elevations of 
either ESR or CRP were used to predict severe disease at 24 hours  a sensitivity and negative predictive 
value of 100% was achieved, and when elevation of both ESR and CRP were utilized at 24 hours  the 
specificity and Positive Predictive Value (PPV) were 100%. (139) This study was conducted in 50 
patients and would require validation in a larger cohort with appropriate statistical power to justify 
regular use of ESR alone or in combination with CRP.    
Median concentrations of ProCalciTonin(PCT) and IL-8 were demonstrated to be significantly higher 
in patients with infected necrosis than in those with sterile necrosis and  there was no difference in CRP 
in the two groups. (140) A PCT value of 3.5 ng/mL on 2 consecutive days was superior to a CRP value 
of 430 mg/L for predicting infected necrosis with Multiple Organ Dysfunction Syndrome (MODS) or 
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non-survival. The sensitivity and specificity of PCT was 93% and 88% and for CRP 40% and 100% 
(p=0.01). (141)    
CRP is synthesized in the hepatocytes as a response to cytokine stimulation and may therefore lag 
behind the initial SIRS. CRP was found to be useful from day 2 to 8 with levels ≥ 210mg/L on days 
2,3 and 4 and ≥120mg/L at the end of the first week when compared to other scoring systems. (142) 
The CRP after 24 hours was superior to the CRP at admission with an area under the curve of 0.68 and 
0,52 respectively. This delayed value of CRP in prognostication was confirmed when CRP at 48 hours 
was superior to CRP assessment at admission, 24 hours and 72 hours in predicting severe pancreatitis, 
pancreatic necrosis and mortality. (143) However in a different finding, CRP at presentation and at 48 
hours did not differ in predicting severe pancreatitis and mortality and CRP at presentation improved 
the prediction of organ failure. (144) This temporal variation of CRP makes it an inconsistent predictor 
of severity.  
Trypsinogen activation to trypsin and the release of Trypsinogen activation peptide (TAP) is an early 
event in acute pancreatitis. TAP is released into the plasma, urine and peritoneum. TAP assays have 
been evaluated as a prognostication factor.   
In a multicentre study from the USA and England which examined 139 patients with acute pancreatitis 
and 50 controls with other acute abdominal conditions, TAP was found to peak at 6-12 hours following 
admission. A TAP value of 10ng/ml obtained within 48 hours was demonstrated to have a 100% 
sensitivity and 85% specificity for predicting severe pancreatitis as defined by organ failure and 
pancreatic necrosis. (121)   
In a subsequent multi-center European study of 246 patients in which 172 had acute pancreatitis and 
74 were controls. A urinary TAP >35 nmol/L, 24 hours after onset of symptoms, was superior to a CRP 
>150 mg/L and an APACHE II ≥8 in predicting severe disease, but at 48 hours all parameters were 
equivalent. (122)   
Trypsinogen has two major isoenzymes which are the Trypsinogen-1(cationic) and Trypsinogen-
2(anionic) forms, an immunochromatographic urinary Trypsinogen-2 dipstick test has been used to 
measure the levels of this isoenzyme. In study from Finland the dipstick for Trypsinogen-2 had superior 
sensitivity and specificity to CRP >150 mg/l and APACHE II > 8 on admission but not at 24 hours. 
(123) TAP assays show promise as accurate predictors of severity but are not readily available and 
require further evaluation including cost analysis in larger patient cohorts.  
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Complements C3a and sC5b-9 measured daily during the first week were noted to have high sensitivity 
(0.93) and specificity (0.88) and high negative predictive value (0.93) and positive predictive values 
(0.87) for a severe outcome but require further evaluation. (145)  
Poor prognosis is related to the extent of local pancreatic necrosis, the severity of the systemic SIRS 
and the development of organ failure. This progression is dependent on the balance between local and 
systemic immune responses. Proinflammatory cytokines determine the systemic response and the 
degree of organ failure whereas ant-inflammatory cytokines seek to limit the inflammation in the 
pancreas. The pro-inflammatory cytokines include IL-1β, TNF-α, IL-6, IL-8, and platelet activating 
factor (PAF) and the anti-inflammatory cytokines IL-10, TNF-soluble receptors and IL-1 receptor 
antagonist have been most frequently assessed in acute pancreatitis.   
Of the cytokines, the pro-inflammatory cytokine IL-6 has been demonstrated to be most useful in 
predicting outcome. It induces CRP synthesis in the liver as part of the response to acute inflammation 
and so serum levels peak earlier than CRP. In a study of 38 patients with acute pancreatitis, IL-6, IL8, 
b2-microglobulin and CRP values were compared on admission and daily for five days. IL-6 had a 
sensitivity of 100%, with a specificity of 86% for severe pancreatitis at a value of ≥ 2.7 ng/L. (146) In 
a study of 80 patients with acute abdominal pain, 40 had acute pancreatitis with 15 having severe 
disease,  
IL-6 at a value of ≥3.7 ng/l, had a sensitivity of 100% and a specificity 83% for detecting severe acute 
pancreatitis. (147) However, serum concentrations of IL-6 decrease rapidly and its use in clinical 
practice has also been limited by the complexity of the assay.(151)  In a study from China on 50 patients 
that evaluated the median peak values on day 1 for TNF-α, IL-1-β, IL-6 and IL-8 and on day 2 for CRP, 
they found that IL-6 was the most useful predictor of severe disease. (149)   
  
2.8.8. Radiological prognostication systems  
Radiological imaging has developed as an important tool in the management of acute pancreatitis. Chest 
radiographs provide information on pleural effusions and the features of adult respiratory distress 
syndrome and pneumonia. CT scan provides information on the early changes in the pancreas as well 
as later complications. The CT scan has emerged as a reliable tool in the assessment of pancreatic 
pathology (150, 151) and has been shown to accurately delineate abnormalities associated with acute 
pancreatitis. (152) These abnormalities have been demonstrated to be predictors of outcome. Early CT 
scan within 5 days has been demonstrated to underestimate disease severity and should be limited to 
cases where there is doubt concerning the diagnosis. (153) The initial description by Balthazar graded 
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the morphological changes in the pancreas at CT scan into 5 grades of A to E. These emphasized fluid 
collections and did not recognize pancreatic necrosis which was later found to be an important 
determinant of outcome in severe disease. Nevertheless, the grades were associated with differing 
outcomes with higher morbidity and mortality in grade E. (154) In the more widely used CTSI 
morphological pancreatic and peripancreatic changes and the extent of necrosis are used to arrive at a 
score which ranges from 0 -10. A score of >6 represents severe disease. (155) The modified version of 
the CTSI incorporates other extrapancreatic changes such as pleural effusions, ascites, splanchnic 
thrombosis and other gastrointestinal changes with a score of > 6 representing severe disease. (156)  
There was no difference between the CTSI and modified CTSI scores in predicting severe disease when 
computed within one week of onset of symptoms. (157)   
There are other CT based severity grading systems which include the renal rim grade (RRG) and the 
extra-pancreatic inflammation on computed tomography (EPIC). These have not been extensively used 
in severity assessment of acute pancreatitis. The renal rim grade is based on the fact that in severe 
pancreatic inflammation, the inflammatory changes may extend beyond Gerotas fascia which is 
normally a barrier against inflammatory extension. The non-inflamed perirenal fat tissue surrounded 
by the inflamed pararenal fat tissue with Gerota’s fascia as the boundary is referred to as the renal rim. 
The loss of the renal rim signifies severe inflammation and is known as loss of the renal rim sign. The 
renal rim has three grades which are associated with the extent of inflammation: grade 1 normal 
pararenal and perirenal spaces, grade 2 attenuation of pararenal space without loss of renal rim sign 
and grade 3 loss of the renal rim sign. The renal rim grades were associated with severe disease in 3%, 
48% and 89% in grades 1, 2 and 3. The mortality rate was 3%, 8% and 31% respectively in patients 
with the three different grades. (158)  
The EPIC score considers extrapancreatic changes (pleural effusion, ascites, mesenteric and 
retroperitoneal changes) while discounting pancreatic necrosis within 24 hours. Values range from 0 
to 7 with a score of ≥4 predicting severe disease. (159)  
These CT based scoring systems are computed after 72 hours and therefore not suitable for early 
prognostication at presentation or in the first 24 hours. However, performing CT on all patients with 
acute pancreatitis is unnecessary as in the majority with mild disease this will be wasteful expenditure. 
CT based prediction of severity has been found to be similar to the clinical scoring systems APACHE 
II and BISAP. (129) This is further mitigation against the use of early CT for the purpose of assessing 
disease severity. CT is of greater value in assessing the complications of acute pancreatitis and guiding 
management. Patients with necrosis of more than 50% of the pancreas are prone to infection and 
multiorgan failure.   
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            2.8.9 Organ failure and pancreatic necrosis  
The development and progression of organ failure and its relationship to pancreatic necrosis are the 
key determinants of morbidity and mortality. However, the relationship between pancreatic necrosis 
and organ failure is not linear and organ failure is found in only half of patients with pancreatic necrosis. 
(160)  In the early phase of acute pancreatitis the severity of disease is determined by the presence of 
organ failure and whether this is transient (less than 48 hours) or persistent (beyond 48 hours). (82)  
The Marshall (Table 6) and Sequential Organ Failure Assessment  (SOFA) (Table 9) scoring systems 
allow stratification of organ failure into degrees of severity and they may be repeated daily. In the 
revised Atlanta criteria, the Marshall score is used to determine the respiratory, cardiovascular and 
renal organ failure. A Marshall score of 2 or more determines organ failure. (44) The Marshall score 
can be used in the initial assessment of all patients whereas the SOFA score is more applicable in an 
intensive care environment in patients on inotropic and ventilatory support. Pancreatic necrosis without 
MODS is unlikely to be associated with mortality.  
 Ideally, prognostication should be feasible at admission to facilitate early intervention in terms of 
specific measures and admission to high dependency areas for those with severe disease. The Ranson 
and Glasgow criteria were validated for use at 48 hours after admission and do not meet this 
requirement. The CRP and APACHE II at 24 hours have been demonstrated to be reliable predictors. 
The BISAP score may be used within 24 hours with similar benefit. However, it is not clear whether 
these systems provide similar benefit in HIV related pancreatitis. Despite these prognostication 
systems, persistent organ failure beyond 48 hours is a reliable predictor of poor outcome. Organ failure 
can be categorized into different severities using the Modified Marshall score and this can be performed 
daily to assess trends. In essence it is early physiological or single marker assessment and as the disease 
evolves the dynamic of organ failure becomes the most important determinant of outcome.   
  
              
             2.9 Management of acute pancreatitis  
There is no specific treatment for acute pancreatitis. The majority of patients have self-limiting disease 
with resolution of symptoms and pancreatic inflammation in a few days and in these patients, 
identifying an aetiology and preventing recurrent disease is the main focus. There are specific therapies 
addressing aetiology and the prevention of recurrent episodes. In severe disease the management is 
geared toward organ support and the management of local and systemic septic complications. In 
patients who survive an episode of acute pancreatitis, further management is aimed at preventing 
recurrent disease.  
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2.9.1 Early management  
In the 20% of patients with severe disease specific measures must be employed to manage the 
complications. It is not clear whether specific measures to address hypertriglyceridaemia (63) and 
hypercalcaemia moderate outcomes. In patients with pancreatic necrosis and organ failure initial 
therapy is organ support in high dependency areas with monitoring for infection  
Fluid resuscitation  
Early fluid therapy is the initial intervention as elevated or rising serum urea levels within the first 24 
hours were associated with mortality. (160) Gut ischaemia has been demonstrated to play a critical role 
in the natural course of severe acute pancreatitis. Reversing this ischaemia early in the disease is a 
widely accepted therapeutic goal. Maintaining an adequate intravascular volume is essential in the 
management of severe forms of the disease. This early resuscitation maintains pancreatic and tissue 
perfusion and may limit the development and extent of pancreatic necrosis. Despite this understanding 
the nature of resuscitation fluid, the appropriate volumes and the timing of intervention and the targets 
of fluid resuscitation have not been settled. (161)   
In a retrospective study of 99 patients, those who received more than 4000ml of fluid in the first 24 
hours had more respiratory complications (65% vs 53%) and intensive care unit admissions (47% vs 
20%) than patients who received less than 4000ml in the first 24 hours. (162)  A study that used changes 
in haematocrit at 24 hours as a marker of fluid resuscitation, showed that all patients with inadequate 
fluid resuscitation (persistent haemoconcentration at 24 hours) developed pancreatic necrosis. (163)  
In patients with severe acute pancreatitis presenting within 72 hours of onset of symptoms, infusion 
rates of 10-15 ml/kg/hour were compared to rates of 5-10 ml/kg/hour. (164) Fluid sequestration in mls 
(5378±2751) vs (4215 ±1998) within 4 days was higher in the first group. The APACHE II scores were 
also significantly higher at days 1,2 and 3 in the first group and so was the rate of mechanical ventilation 
(94% vs 65%). Abdominal compartment syndrome and sepsis were lower in the second group whereas 
survival was lower in the first group (69.4% vs 90%, p < 0.05). This study concluded that the higher 
fluid resuscitation protocol was not beneficial to patients within 72 hours of the onset of severe acute 
pancreatitis.  
In a study by Gardner, on 45 patients presenting with severe acute pancreatitis, a comparison was made 
between two groups who received ≥ or ≤ 33% of their 72-hour fluid requirements within the first 24 
hours. Patients with ≤ 33% fluid resuscitation regimen had a higher mortality (18% vs 0%) and a trend 
towards a higher rate of persistent organ failure (43% vs 35%). (165) There was no difference in the 
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fluid administered during the first 72 hours suggesting a benefit from more aggressive resuscitation 
within the first 24 hours of presentation.  
The nature of fluid to be used in resuscitation is also controversial. Infusions of large volumes of normal 
saline are associated with hyperchloraemic acidosis. In a pilot study which compared Ringers lactate 
and normal saline fluids, there was a significant reduction in SIRS after 24 hours in patients resuscitated 
with lactated Ringer's solution (84% vs 0%). (166) In a study from Scotland which compared survivors 
and deaths from severe acute pancreatitis, the cumulative volume of crystalloid given at 48 hours in 
patients who died was less than in survivors (3331 ± 800 ml vs. 7287 ± 544 ml). Patients who died 
were found to have received lower fluid volumes with higher median central venous pressures of 18 
mmHg (range 15-19) vs 11 mmHg (7- 14) The use of central venous pressure as a marker of adequate 
fluid resuscitation was found to be unreliable. (167)       
Until better powered trials are completed Ringer’s Lactate should be the preferred crystalloid solution 
for the early resuscitation of patients with acute pancreatitis. Fluid resuscitation in acute pancreatitis is 
pertinent in severe forms of the disease. Rather than adhering to specific volumes and rates, the fluid 
requirements are tailored to individual requirements utilizing a number of critical care tools such as 
cardiac and renal output, inotropic requirements, central venous pressure, end tidal C02 and other 
markers of tissue perfusion.   
Early interventions in biliary, hypercalcaemia, hypertriglyceridaemia associated pancreatitis  
Gallstone pancreatitis  
The need for early intervention in gallstone pancreatitis with biliary decompression by ERC is 
controversial with a number of conflicting reports. Biliary pancreatitis is caused by migrating stones 
and the duration of ampullary obstruction by migrating stones beyond 48 hours is associated with more 
severe pancreatitis.(168,169) Common bile duct (CBD) stones were also found in 75% of patients 
operated on within 73 hours and 28% of those having an elective cholecystectomy after discharge in a 
study by Stone in 1981. (170)   
The initial trials on ERCP in gallstone pancreatitis were performed non-selectively in patients with 
gallstone related pancreatitis with conflicting results. When ERCP within 72 hours was performed non-
selectively in 55 patients with gallstone related pancreatitis, 37(67%) were demonstrated to have 
choledocholithiasis and choledocholithiasis was more frequent in predicted severe than predicted mild 
disease(57% vs 29%). (171) When ERCP was performed non-selectively within 72 hours in 59 of 121 
patients with gallstone related pancreatitis, there were fewer complications and shorter hospital stay in 
those subjected to ERCP. (172) In a subsequent study by Fan in 1993 on 127 patients non-selective 
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ERCP resulted in decreased biliary sepsis but not other complications of pancreatitis. (173) The 
decrease in biliary sepsis was similar in mild and severe pancreatitis.   
Subsequent studies have been performed more selectively in patients with gallstone pancreatitis.  
Patients with biliary obstruction without cholangitis (bilirubin >20.52 umol/l), were randomized to 
urgent ERCP (within 24 hours) and early ERCP (24-72 hours). There was no differences in ERCP 
related complications or in hospital stay. (174)  
In a 2007 study by Oria, early ERCP and papillotomy in patients with gallstone pancreatitis and biliary 
obstruction did not result in a lower mean organ failure score or mean CT severity index, lower 
incidence of local complications or mortality if there were no associated features of cholangitis. (175) 
A meta-analysis of three trials which included 450 patients was performed by the Dutch Pancreatitis 
Study Group to determine the outcomes of early ERCP in non-selected patients with acute biliary 
pancreatitis without cholangitis. The findings were that early ERCP was associated with a non-
significant decrease in complications and a non-significant increase in mortality and these findings 
were not altered by analysis according to disease severity. (176) In a subsequent prospective study the 
same group demonstrated that complications were significantly lower and mortality insignificantly 
lower when ERCP was performed within 72 hours in patients with predicted severe acute pancreatitis 
associated with cholestasis. (177) They concluded that early ERCP is most beneficial in patients with 
predicted severe disease with cholestasis.  
The interpretation of the most recent results has led to the current recommendations; urgent ERCP in 
patients with severe disease and cholangitis and ERCP at 72 hours in patients with mild disease and 
cholestasis. Cholecystectomy should be performed within the same admission.  
Hypertriglycerideaemia  
Whether early treatment to lower triglyceride levels improves clinical outcomes is not clear but there 
are reports suggesting that patients with severe hypertriglyceridaemia have a more severe course of 
acute pancreatitis with 71% having severe disease in a Dutch study.(178) The appropriate methods 
employed for reducing triglyceride levels > 10mmol/l and improving outcomes is controversial.(67) 
Measures beyond standard therapy are considered unnecessary by some authors.(179, 180) whereas 
others have proposed additional measures such as low dose heparin and insulin infusion (181), plasma 
exchange and plasmapheresis.(182) Initial local experience suggests that measures beyond initial 
starvation and monitoring of the reduction of levels are unnecessary.(67)   
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Hyperparathyroidism   
Surgical treatment of hyperparathyroidism prevents reccurent pancreatitis in patients with 
hypercalcaemia. It has not been investigated whether therapy intended to lower the calcium levels at 
presentation improves outcomes in severe forms of the disease.  
Nutritional interventions  
Acute pancreatitis, especially the severe form, is associated with activation of systemic inflammatory 
pathways, complement cascade, oxygen derived radicals and arachidonic acid metabolites. These result 
in the production of acute phase proteins and loss of lean body mass. This is exacerbated by the lack 
of nutritional intake, increase in gut permeability, bacterial translocation and sepsis. Initially nutritional 
support in acute pancreatitis was based on the initial practice of fasting the patient in order to rest the 
pancreas and prevent enzyme secretion and further autolysis. This lack of nutrients to the gut wall 
resulted in structural and functional abnormalities with bacterial translocation and inflammation as a 
result. The inflammation increased the resting energy requirements and exacerbated the lean body mass 
loss. Parenteral nutrition served, the understanding then of, a need to rest the pancreas and counter the 
catabolic response. When used in all patients with acute pancreatitis, total parenteral nutrition was 
found to be of no benefit in reducing the days to oral intake and hospital stay or the development of 
complications in 54 patients randomized to the conventional therapy of fasting or total parenteral 
nutrition in 24 hours. (183) The improved understanding of the pathophysiology of pancreatitis resulted 
in the institution of early enteral nutrition. In the majority of patients with mild acute pancreatitis early 
enteral feeding is possible and may improve recovery but has no bearing on morbidity or mortality. 
(184) Early enteral nutrition using a nasojejunal feeding tube within 60 hours of onset was not 
associated with adverse events in predicted severe acute pancreatitis in 21 patients. (185)  
Infectious complications, multiple organ failure and mortality were significantly lower in patients who 
received total enteral nutrition as opposed to total parenteral nutrition within 72 hours of the onset of 
symptoms. (186) In a randomized controlled study of patients with predicted severe disease by the 
APACHE II score of ≥8, CRP  > 120mg/L and Balthazar grade D or more, patients fed nasoenterally 
within 48 hours had fewer septic complications than patients fed by total parenteral nutrition. (187) 
Other complications, hospital stay and mortality did not differ. Nasoenteral feeding was also cost 
effective. Subsequently enteral nutrition was demonstrated to diminish the acute phase response and 
the disease severity when compared to parenteral nutrition. (188) However it has also been 
demonstrated that enteral nutrition did not improve the inflammatory response or intestinal 
permeability. (189)  Nasogastric feeding was demonstrated to be more easily accomplished than 
nasojejuna feeding  without worsening symptoms or negatively affecting outcomes. (190)     
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Modulating the nutritional content to achieve specific nutritional or immunological goals has followed 
on from the acceptance that early enteral nutrition is feasible and beneficial. The addition of glutamine 
to parenteral nutrition in acute pancreatitis was associated with a significant increase of cholinesterase, 
albumin and lymphocyte count and a decrease of CRP when compared to standard parenteral nutrition 
at day 14. Glutamine was also associated with a reduced length of parenteral nutrition [10 days {range 
6–16} vs 16 days {range 10–18} (p<0.05)] and a trend towards reduced length of hospital stay [21 days 
{range14–32} vs 25 days{19–40}]. (191) Glutamine, Arginine and Omega-3 fatty acids have been 
shown to have immune-enhancing properties in the gut epithelium. (192) In a meta-analysis of three 
randomized controlled trials which included 78 patients in which Glutamine, Arginine and Omega-3 
fatty acids were administered nasoenterally to 40 patients and standard nutrition to 38 patients. 
Infectious complications developed in 12(30%) of the immuno-nutrition group and 14(37%) of the 
standard enteral nutrition group without a significant reduction in the risk of infectious complications 
(RR 0.82; 95% CI 0.44 to 1.53),(193) Mortality between the two groups was also not significantly 
different (RR 0.64; 95% CI 0.20–2.07)   
In patients with mild disease early feeding is possible but nutritional intervention does not affect the 
outcome. In severe disease, current understanding suggests that nutrition should be instituted within 
48hours. The preferred route should be enteral even if only small amounts of immuno-nutrition can be 
delivered. Nasojejunal or nasogastric routes are equally effective. Patients with severe ileus will require 
parenteral feeding initially and this should be converted to an enteral route when gut function resumes.   
 
Antimicrobials in acute pancreatitis  
Advances in critical care and the use of antimicrobials resulted in a significant decline in the mortality 
rate of acute pancreatitis (Figure 2). This was as a result of management of general septic 
complications. Severe forms of acute pancreatitis often manifest an early significant systemic 
inflammatory response with capillary leak and hypovolaemia which may result in cardiorespiratory 
and renal complications and death. Patients who survive this initial phase in intensive care enter a later 
phase in which they are at risk of developing infectious complications which may include infection of 
the necrotic pancreas. The role of antimicrobials in preventing infection of necrotic pancreas is 
controversial.   
Bacterial infection and the extent of pancreatic necrosis determine the incidence of organ failure 
independently. (194) In patients with sterile necrosis organ failure was determined by the extent of 
necrosis and the incidence of infection was associated with an increase in the extent of pancreatic 
necrosis. Infected necrosis is associated with a high incidence of organ failure. Infecting organisms in 
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most series are composed of Gram positive bacteria (Staphylococcus. Enterococcus, Streptococcus), 
Gram negative bacteria (Escherichia coli, Klebsiella) and Fungi (Candida, Cryptosporidium). (195, 
196)  
In HIV associated pancreatitis opportunistic infections such as Pneumocystis carinii and 
Mycobacterium avium intracellulare have been demonstrated. (24) This results in HIV patients in a 
larger spectrum of organisms including viruses both systemically and in the necrotic pancreas.   
Selective gut decontamination was found to prevent septic complications of the pancreas and resulted 
in lower morbidity and the need for operation. (194) However, mortality was not significantly altered. 
Probiotics were an alternative therapeutic intervention based on their ability to alter the intestinal flora 
and reduce bacterial translocation with its attendant septic complications. An initial trial showed 
promise in reducing the pancreatic septic complications (197) however the subsequent Probiotics in 
Pancreaitis Trial (PROPATRIA) has dampened enthusiasm for this therapeutic avenue when it reported 
that the only mortalities were in the probiotic arm. (195)  
The trials of antimicrobial agents in acute pancreatitis are summarized in Table 10. (13, 198-210)  
When examining trials which have addressed antimicrobial use; the agents used varied, the dosage and 
duration was not uniform and patient allocation methods and the blinding processes were unclear. In 
addition, two agents were used in some of the trials and the number of patients investigated were small. 
Beger has demonstrated that infection of the necrotic pancreas is dependent on the extent of the necrosis 
and the duration of necrosis with the majority of infection occurring after two weeks. (211) Some trials 
examined not just infection of the necrotic pancreas but also pulmonary, urinary tract and blood. (199) 
Antimicrobials have also been assessed in alcohol as a single aetiology group where they showed 
benefit. (199, 200) However it is unclear how generalizable these results are in the other common 
aetiology, gallstones. The study by Dellinger in 2007 did not demonstrate any benefit in the reduction 
of sepsis, mortality or surgical intervention when Meropenem was used in 50 of 100 patients with 
confirmed necrotizing pancreatitis in a multi-centre trial involving European and United States of 
America centres. (13) 
A subsequent meta-analysis has also determined that routine antibiotic prophylaxis does not prevent 
septic complications or reduce mortality. (212) This review concluded that prior studies were 
underpowered and that Imipenem may have benefit in preventing infection in CT scan proven 
pancreatic necrosis. Many studies are confounded by the variable proportion of patients who die early 
before the pancreatic necrosis has become infected and hence the benefit of antimicrobials cannot be 
measured in these patients. (Table 11) IL-6 and PCT measured soon after hospital admission were 
associated with infection of pancreatic necrosis and their use to determine the need for antimicrobial 
therapy requires further evaluation. (213) 
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Routine early use of antimicrobials is not current practice. Antimicrobials are unlikely to significantly 
reduce mortality in the early phase as this is largely a sterile insult. Empiric antibiotics should be 
commenced only when there is suspicion of infection and altered to directed therapy when the 
offending organism is identified. In HIV related pancreatitis opportunistic and viral infections are part 
of the spectrum and should be considered when antimicrobial therapy is deemed necessary. A potential 
to improve the rational for antimicrobial therapy is better selection of patients who may benefit, using 
IL-6 and procalcitonin measurement soon after hospital admission.  
2.8.2 Late management  
 
The management of infected pancreatic necrosis is controversial and dependent on local expertise and 
experience. Intervention is contraindicated early in the process as mortality is high regardless of 
intervention. Pancreatic necrosis with signs of systemic sepsis indicates the need to consider the 
diagnosis of infected pancreatic necrosis. Infected pancreatic necrosis however diagnosed requires 
intervention if it is associated with organ failure. Traditionally open surgery techniques which included 
open packing, repeat laparotomy, closed packing and closed continuous lavage were utilised. Table 12 
(214-225) is a review of the outcomes of open surgery and demonstrates that mortality rates range 
between 6% and 39% and that a rate of 15% has been achieved by all techniques in experienced centres. 
The morbidity rate for pancreatic fistula ranged between 14% and 88% and bleeding complications 
between 5% and 83%.    
Because of high morbidity and mortality of open surgery, minimally invasive staged necrosectomy has 
been utilized as initial management which may be definitive or act as a bridge to allow optimization of 
organ failure prior to open surgical intervention. A number of techniques have been devised utilizing 
percutaneous drainage with saline flushes, laparoscopic drainage, video assisted retroperitoneal 
debridement (VARD) and transluminal endoscopic techniques. (226, 227) The results of these 
approaches are evaluated in Table 13. (228-235, 218-219, 234-239, 225)  The morbidity and mortality 
rates range widely between 10% and 88%, and 5% and 40% respectively due to the heterogeneity of 
the study populations.    
Diagnosis of infected necrosis may be a challenge as these patients are frequently in high dependency 
environments and physiologically unstable. In many instances the clinical suspicion will guide 
intervention. These include non-resolving features of sepsis and clinical deterioration. There exists a 
need for biochemical markers of infected necrosis which can direct further evaluation. In a study to 
assess the predictive value of PCT and IL-8, patients with infected necrosis had significantly higher 
median concentrations of PCT and IL-8 than those with sterile necrosis. There was no difference in 
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CRP between the 2 groups. This was in patients in whom serum samples were drawn daily for 2 weeks 
and the diagnosis of infected necrosis was made at a median of 13.5 days from admission. (140) The 
aim of the study was to select patients for antimicrobial prophylaxis in those with pancreatic necrosis, 
serum levels of IL-6, TNF-α, CRP and PCT were assessed during the first 3 days after admission. (213) 
PCT and IL-6 were markedly higher and differed between patients who developed infection and those 
who had a negative culture when CT scan and needle aspiration of pancreatic necrosis was performed. 
There was no difference in the TNF- α and CRP in these 2 groups. The combined use of IL-6(<400 
pg/L) and PCT (< 2 ng/L) best predicted patients not at risk for infection with sensitivity, specificity 
and negative predictive values of 75%, 84% and 91% respectively.   
A larger cohort of 104 patients with predicted severe pancreatitis in 5 European centres were evaluated 
with PCT and CRP. (141) Both parameters were measured daily for 21 consecutive days and weekly 
thereafter. Significant elevations in PCT were associated with pancreatic infection accompanied by 
MODS in patients who did not survive the pancreatitis. These changes were found early after onset of 
symptoms. In contrast PCT elevations were moderate in pancreatic infections without MODS. CRP did 
not show similar changes. A PCT value of ≥3.5 ng/mL was significantly better than a CRP value of ≥ 
430mg/L on the initial 2 consecutive days for determining infected necrosis with MODS or death (P < 
0.01)) This difference in prediction of poor outcomes was still evident on the third and fourth days (P 
= 0.002) (Table 14).    
  
Evolution of surgical therapy  
The evolution of the management of acute pancreatitis since the first clinical description is presented 
in Figure 2 and details the changes in the place of surgery and the subsequent influence of 
advancements in critical care, antimicrobials and minimally invasive procedures on mortality.   
Initially the majority of patients were diagnosed intra-operatively and early surgical intervention was 
considered appropriate though only few survived surgery. In 1889, Fitz reviewed the presenting 
symptoms, signs, aetiological associations, local complications and different pathological 
classifications. (246) He set out the initial criteria for an antemortem diagnosis of acute pancreatitis. 
He initially considered surgery as unhelpful and later recognised some benefit in selected patients. In 
1894 Werner Körte performed surgical drainage of an abscess complicating acute pancreatitis. He 
advocated delayed surgical intervention as early surgery was associated with poor outcome. (247) 
Despite these conservative recommendations, a prolonged period of the primacy of surgery in acute 
pancreatitis followed in the early decades of the 20th century. Moynihan was convinced that recovery 
was unlikely without surgical intervention despite the lack of agreement on the nature of the 
intervention. (248)  He advocated debridement and drainage of the lesser sac.  In 1927, Schmieden in 
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a review of 1510 cases of acute pancreatitis found a mortality rate of 51% in the 1278 patients subjected 
to surgery. (249) He advocated early surgical intervention despite their findings of 24% and 65% 
mortality rates in the oedematous and necrotizing pancreatitis respectively.   
The introduction in 1929 of the biochemical marker serum amylase enabled the diagnosis of acute 
pancreatitis without the need for surgery. This allowed the clinical differentiation between mild and 
severe forms and the recognition that acute pancreatitis had a mild and self-limiting course in the 
majority of cases, that did not require surgery. (110) The paradigm shift from frequent surgical 
intervention to initial non-operative intervention was strengthened by a 1948 analysis of a series of 307 
patients that revealed a surgical mortality of 45% and a non-operative mortality of 28%. (250)  
A selective approach to surgical intervention became the norm with surgery reserved for those who 
showed clinical deterioration after the initial phase of resuscitation and cardiorespiratory support. (251) 
Surgery was also reserved for cases of diagnostic doubt since the clinical and biochemical parameters 
were not specific for pancreatitis in these patients and most of the possible differential diagnoses 
required a laparotomy for management. (252)    
Interventions are currently restricted to patients who develop compartment syndrome, perforated bowel 
and infected pancreatic necrosis. Open surgical techniques for infected necrosis were practiced over 
decades and more recently this has been superseded by minimally invasive techniques which use a 
delayed step up approach using percutaneous or endoscopic techniques singly or in combination to 
provide staged drainage. (232, 253)   
2.8.3 Mortality  
At the beginning of the 20th century mortality rates in acute pancreatitis reached 60%. (254) The use 
of positive pressure ventilation in the 1940s resulted in a decline in mortality to 18%. (255) In the 
period 1969-1979 a further reduction to 7.8% was observed. (256) Subsequently in the decade from 
1984 to 1995 there was a decline from 9.1% to 6.6% despite an increase in the overall number of 
fatalities. (5) These improvements in survival were associated with advances in respiratory, cardiac and 
renal support and, antimicrobial therapy in critical care settings.   
Recent investigations demonstrated that death in acute pancreatitis is an early (<2 weeks) or late (>2 
weeks) event. Early mortality results from a severe SIRS which may progress to multiple organ failure 
and death. Late mortality is a result of septic complications. (257) The management of patients in these 
2 phases of the disease differs as the initial treatment is supportive with attention to organ failure and 
the latter may require intervention to address infected necrosis. Table 11 (2, 4-10, 14-18, 21, 23, 139, 
258) illustrates the proportion of early and late mortality in various trials and in previous studies from 
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South Africa most (67-79%) mortalities were early within two weeks. (3, 5-8, 14, 15, 17, 20, 22, 67, 
110, 225) The global trend is towards a greater proportion of mortality within two weeks. There was 
no significant difference between early or late mortality in terms of age, gender distribution, aetiology, 
predictors of severity, BMI, comorbidity and year of admission. (14) Early deaths were associated with 
multiple organ failure and late deaths multiple organ failure and infected necrosis. In a large study of 
13727 patients between January 1984 and December 1995, 53.7% of patients died in the first week of 
hospitalization with a range 61.7%- 49.1% over that period. The majority (78.4%) of early mortalities 
were in patients older than 60 years but the proportion of early and late mortalities was similar in all 
age groups. (5)  
Aetiology has not been demonstrated to influence mortality in most settings but a study from Korea 
demonstrated that an alcohol aetiology when compared to a biliary aetiology had a more severe course 
with pseudocyst formation (20% vs 7%), organ failure beyond 48 hours (24% vs 1%) and a significantly 
higher mortality (8% vs 0%). (45)   
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SECTION 2: HIV INFECTION  
2.9 Epidemiology of HIV infection 
HIV belongs to the Retroviridae family and the Lentivirus genus. Lentiviruses cause slow, unremitting 
disease targeting lymphocytes and differentiated macrophages in the host. It is a retrovirus with its 
genetic information encoded in RNA and requires reverse-transcription into DNA by viral reverse 
transcriptase for replication. (253) In infected individuals, the virus is present in the blood, semen, 
rectal fluids, vaginal fluids and breast milk. The main routes of transmission are sexual contact, mother 
to child before or during birth or with breastfeeding and sharing contaminated needles for injectable 
substances or needle injuries in health professionals. (254) HIV infection transmission is positively 
influenced by viral load and associated genital ulceration. (255) Viraemia and hence transmission is 
higher in the 3 months after primary infection just prior to seroconversion and late in the disease before 
death. (256) The virus may infect a number of different cell types but the main target is CD4 T-cells. 
It may also infect CD4+ macrophages and dendritic cells. (257)   
In a 2016 report an estimated 37 million people were living with HIV infection worldwide and 70.8% 
of them were in sub-Saharan Africa. (257) The age and gender distribution of HIV infection in 
KwaZulu Natal province is shown in Figure 3. In this province as in the rest of sub-Saharan Africa, 
the spread of the virus is predominantly by mother to child or heterosexual transmission. The world 
prevalence increased from 31 million in 2005 to 35.3 million in 2012 as people are living longer with 
treatment. This was despite a decline in the incidence of new infections from 3.3 to 2.3 million over 
the same period as a result of a decline in heterosexual transmission while homosexual transmission 
remained the same. The reduction in transmission is the result of effectively screened blood donations, 
increased use of HAART, perinatal HAART, male circumcision and drug infused vaginal gels. (258) 
Despite these measures, transmission during the acute infection phase remains problematic and cure of 
HIV viral infection by vaccination is hampered by the virus being inaccessible when it enters a latency 
phase in different cell types and its high genetic diversity. (253, 259-261) In a national survey in South 
Africa in 2012, 31.2 % of HIV+ve individuals were on treatment with HAART. (25)  
2.10 Aetiology and pathogenesis of HIV infection   
HIV has been shown to have extensive genetic heterogeneity, between individuals and within an 
individual. The heterogeneity is largely located in the gene encoding the envelope glycoprotein, gp 
160. Genetic diversity within an individual, increases by 1% annually. (262)  
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HIV-1 and HIV-2 are the dominant HIV virus strains. HIV-1 is the predominant strain in South Africa 
and Southern Africa. HIV-2 causes a slower decline in CD4+ T-lymphocytes, longer periods of 
asymptomatic infection and lower mortality rates than HIV-1 infection. (263) 
Primary HIV infection may range from asymptomatic seroconversion to a severe illness requiring 
hospitalization. (264) Symptoms which are commonly associated with primary HIV infection are fever, 
sore throat, fatigue, weight loss and myalgia with physical examination revealing postural hypotension, 
oral ulceration, exudative pharyngitis, thrush, genital or rectal ulceration, lymphadenopathy and signs 
of neuropathy. Signs and symptoms of aseptic meningitis fever, headache, photophobia and neck 
stiffness may also be present. As these features are not specific to HIV, the infection may be missed at 
this point. At the primary infection, the viral load rises and there is a rapid decline in the CD4 
lymphocyte count. The immune response at seroconversion eventually contains the viral replication 
and the viral load will decline to levels lower than 1% of the peak levels. There follows a period of 
stable viral levels without symptoms. (265) There is a temporal relationship between infection and the 
emergence of HIV RNA P24 antigen which is shorter than the time taken to develop antibodies to the 
virus. P24 antigen testing has shortened but not eliminated the window period of infectivity prior to the 
diagnosis when sexual contacts remain vulnerable to acquiring the infection,.  
Figure 4 shows the temporal relationship of the HIV diagnostic assays superimposed on a graphical 
depiction of the kinetics of circulating HIV RNA, p24 antigen and HIV antibodies. It shows the times 
to reliable positivity of the five generations of tests with the nucleic acid amplification test now being 
the  preferred test. (266)  
During the chronic phase the CD4 levels will decline to very low levels in untreated individuals 
rendering the host susceptible to opportunistic infections such as Mycobacterium avium, Pneumocystis, 
Cryptococcus neoformans, Toxoplasma gondii and Cytomegalovirus or to tumours such as Kaposi’s 
sarcoma and B-cell lymphomas. Some patients will develop neurological dysfunction and HIV 
associated nephropathy. (267)  
In some patients chronic inflammation persists despite undetectable viraemia and is associated with a 
poorer outcome. The persistent inflammation is explained by preferential depletion of the CD4+ helper 
cells in the gut mucosa which results in bacterial translocation and inflammation. (268) A persistently 
elevated CRP level (>5mg/dl) at presentation and 24 weeks after initiation of HAART was associated 
with disease progression when compared to persistently low levels or an isolated elevation in CRP. 
(269) The combination of elevated CRP(>10mg/l) and anaemia (females<12mg/dl, male<13mg/dl) 
prior to HAART was associated with treatment failure after initiation of HAART. Treatment failure 
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was defined as stage 3 (symptomatic infection with opportunistic infections), stage 4 (CD4 drops to 
<200 and worsening opportunistic infections) or death at 96 weeks. (270)  
It is unclear which factors influence outcome in HIV infected patients who present with critical illness 
that requires organ support. In a study assessing HIV infected patients admitted to ICU for various 
diseases there was no difference in mortality between patients admitted with sepsis and patients 
admitted with SIRS of a non-infectious aetiology. In the same study a low CD4 lymphocyte count was 
not associated with an increased mortality rate, but three (75%) of the ICU admissions with pancreatitis 
died. (43)    
2.11 Mortality in HIV infection  
A survey of mortality in 78,000 HIV-infected patients from France reported 964 in 2000 and 1042 
deaths in 2005. (271) AIDS related deaths accounted for 36% of deaths in 2005 and 47% of deaths in 
2000. Eleven percent (2000) and 9% (2005) of patients died within 6 months of initial presentation. 
Non- Hodgkin Lymphoma was the most common cancer related cause of mortality in all patients. The 
median age of death increased from 41 years in 2000 to 47 years in 2005. The median duration of HIV 
infection increased from 8 to 12 years and the number on HAART was 87%, up from 86%. The mean 
CD4 count was 94 in 2000 and 161 in 2005. (271)  
Patients with HIV infection treated with HAART have been found to have premature cardiovascular 
associated mortality purported to be caused by the HAART side effects of fat redistribution, 
dyslipidaemia and insulin resistance. (272)  
In a Danish population based cohort observational study over the period 1995-2005 the median survival 
from 25 years of age at initial observation was 19.9 years (95% CI,18.5 to 21.3) in patients with HIV 
infection and 51.1 years (CI,50.9 to 51.5) in the general population. For HIV-infected patients, survival 
increased to 32.5 years (CI, 29.4 to 34.7) over this period illustrating the benefits from HAART. (273)  
In South Africa the survival times were 80-82% and 82-84% of those in HIV negative individuals for 
men and women respectively when calculated in individuals commencing HAART at 35 years of age 
with a baseline CD4 count of 200 or higher. (274) This study did not provide data on survival in HIV-
ve individuals.  
In an American cohort of 4241 HIV infected participants evaluated from 1990 to 2003, 1224 (28.9%) 
deaths occurred with 987 deaths prior to HAART and 237 in the HAART era. The 237 deaths included 
159 deaths in the early HAART era (1997–1999) and 78 in the late HAART era (2000–2003). There 
was an 80% decrease in deaths from 1990 to 2003. In this period AIDS defining causes of death 
declined from 80% to 56% and non HIV related causes of death increased from 9% to 32% and death 
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as a result of opportunistic infections declined from 59% to 24%. Liver disease as the primary cause of 
death increased from 0.2% to 3.7%. The number of deaths associated with CD4 cell counts of less than 
200 cell/mm3 declined from 93% to 61% in the same period. (275) 
These observations demonstrate a benefit in survival from HAART and although acute pancreatitis is 
frequently associated with HIV infection it is not among the commonest causes of mortality. HAART 
has resulted in increased CD4 counts and a decline in AIDS defining causes of death. 
 
                                                                                                                                                                                                                                    
Section 3: Overall summary of chapter  
 
Amylase and lipase are enzymes that are most frequently used adjuncts to confirm the clinical diagnosis 
of acute pancreatitis. Lipase has been demonstrated to more useful because of a higher specificity than 
amylase. Establishing the aetiology and severity of the disease is key to effective management. 
Gallstone pancreatitis can be reliably diagnosed and managed effectively to prevent recurrence. 
Severity assessment allows patients to be identified to allow appropriate organ support and further 
assessment for the presence and extent of pancreatic necrosis and guides further management. Infected 
pancreatic necrosis with organ failure requires interventional management to reduce mortality. These 
management principles are well elucidated in HIV-ve patients but not in HIV+ve patients  
HIV infection is associated with both asymptomatic and symptomatic elevations in amylase. This draws 
into question whether these enzymes are effective diagnostic adjuncts in HIV infected cohorts. In South 
Africa, over the past decade, there has been a rise in acute pancreatitis cohorts of HIV+ve patients but 
there is no information on the incidence of acute pancreatitis in both the general and HIV populations.  
Although most cases of acute pancreatitis are associated with gallstones and alcohol, in HIV infection 
there are many potential additional aetiological associations which include drug therapy, opportunistic 
infections and malignancies. In reports from regions with HIV infection prevalence rates of less than 
1% there was a decline in the acute pancreatitis incidence in HIV infected individuals although this 
remains higher than in the general population.   
Early prognostication is crucial in the management of acute pancreatitis to facilitate the identification 
of severe disease which may result in morbidity or death. The APACHE II score has been demonstrated 
to be effective and the BISAP score simple and applicable to lower levels of care. These have been 
studies conducted in countries with a low HIV prevalence. Since HIV infection and antiretroviral 
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medication is associated with deranged liver function tests, altered immunity and white cell counts, it 
has not been established whether the prognostic markers are suitable for use in HIV infected cohorts 
with acute pancreatitis which may have varying degrees of alteration in inflammatory markers and 
other biochemical and haematological parameters.  
Since HIV infection is associated with opportunistic infections and these have been demonstrated in 
the pancreas in post-mortem investigations, it is not clear from previous studies whether opportunistic 
infections are a major factor in determining outcomes in HIV associated pancreatitis. There is no clear 
picture of outcomes in HIV associated pancreatitis with some demonstrating worse outcomes and 
others not demonstrating any differences with HIV-ve related pancreatitis.   
This study aims to address these deficiencies by directly comparing the hospital prevalence of acute 
pancreatitis and the rate of associated HIV infection.   
A study into the aetiological association between HIV infection and acute pancreatitis is highly 
pertinent and appropriate to South African clinical practice where the prevalence of HIV in the 15-49 
year old population group is 19.2%.  The few studies in a South African context have demonstrated an 
increase in the prevalence of HIV infection in patients presenting with acute pancreatitis. However, 
these studies involved patients in whom HIV testing was not performed in all patients and hence they 
are likely to have underestimated the prevalence of HIV infection in patients with acute pancreatitis. 
Theses deficits set the frame work to formulate the study aim that seeks to address the paucity of critical 
analysis of the relationship between HIV infection and pancreatitis in an environment with a high 
prevalence of HIV infection.   
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CHAPTER 3: METHODS   
3.1 Design   
The study is a prospective descriptive analysis of acute pancreatitis and trauma cohorts with universal 
counselling for HIV infection testing. The hypotheses to be tested are detailed in Chapter 1.  
3.2 Study location and period  
Prince Mshiyeni Memorial and Addington Hospitals in Durban over 2 years for data collection and 
analysis.   
3.3 Study population  
Patients were sourced from the emergency departments at Addington and Prince Mshiyeni Memorial 
hospitals within the Durban metropolitan functional region of the KZN Province. Addington hospital 
has a mixed racio-ethnic referral base derived from its urban and peri-urban population in the central 
and northern parts of the metropole. Prince Mshiyeni Memorial hospital has a largely indigenous 
African referral base serving the urban, peri-urban and rural population in the south of the metropole 
and the province. Racio-ethnic analysis was also included due to the marked variation in the prevalence 
rates of HIV infection with these designations. Racio-ethnic groups were self-declared in the study. 
3.4 Data collection and tools   
Patients included in the study were 18 years and older. Data related to demographics, biochemical 
investigations, aetiology, imaging, endoscopic procedures, surgery and outcomes were collected 
directly into a password protected spread sheet using Microsoft excel.  
Patients were included in the study sample if they presented with the typical symptoms of sudden onset 
of epigastric pain and an elevated serum amylase or lipase of at least 3 times the upper limit of normal, 
or a urine amylase >1000 IU/L. Biochemical, haematological and clinical parameters used in assessing 
predictors of severity were assessed within 24 hours of presentation (SIRS, Glasgow, APACHE II, 
CRP and BISAP). This was temporal assement was choosen because  of the  interest to make the earliest 
prognosticalion possible as this as this would allow more accurate triage at an earlier stage. The scoring 
systems were assessed for their accuracy in stratifying patients into mild, moderate and severe disease 
according to the revised Atlanta criteria. (48) Alcohol use was sought in the history(daily consumption 
or binge drinking) and transabdominal ultrasound examination was used to determine gallstones as the 
cause of pancreatitis. All trauma and acute pancreatitis patients were counselled for HIV testing if their 
status was not declared and verified to be correct.  Known HIV+ve patients were asked whether they 
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were receiving HAART and if so, what drugs they were receiving. Chest and abdominal x-rays and 
ultrasound were used at presentation to screen for other pathological conditions with similar 
presentations to acute pancreatitis.  CT was used to assess for complications of acute pancreatitis in 
patients who did not show improvement in the first week or had severe disease. A pancreas protocol 
was performed in three phases. An initial non contrast scan was performed from the diaphragm to the 
Iliac creast. Three cups of water were given orally every 10-15 minutes prior to commencing the scan. 
Contrast (100ml Omnipaque) was injected intravenously at 3mls/second.  Parenchymal and portal-
venous phases were then acquired at 40 seconds and 80 seconds after contrast injection by scanning 
from the diaphragm to the Pubic symphysis. Renal function requirements for contrast administration 
are urea > 12mmol/l, creatinine <130 mmol/l and a glomerular filtration rate > 45. Patient with renal 
function worse than the presets will require periprocedural dialysis on a non contrasted Magnet 
Resonance Imaging (MRI). MRI was not performed in this group of patients. Antimicrobials were not 
prescribed routinely and were prescribed empirically when infection was suspected or using specific 
directed antimicrobial therapy when an organism was identified or cultured.  
HIV was diagnosed by the use of 2 serial rapid third generation tests.  An Enzyme-Linked  
Immunosorbent Assay (ELISA) was used when the tests were discordant or weakly positive. The 
Advanced Quality Rapid Anti-HIV Test was used as the initial test. It has been found to have a 100% 
sensitivity and specificity when compared to Enzyme linked immunoassay (EIA) and Western Blot as 
reference points. The HIV 1/2/0 Tri-line Rapid test was used as the second confirmatory test. When 
compared to ELISA and the Western Blot it was found to have a sensitivity of 99.9% (99.4-100%), 
specificity of 99.8% (99.5-99.9%) and relative accuracy of 99.8% (99.6-99.9%).  
3.4.1  Patients  
Inclusion / exclusion criteria  
Epigastric pain associated with one of the following: an elevated serum amylase or lipase greater than 
3 times the upper limit of the normal or an ultrasound or CT with features of pancreatitis or findings 
of pancreatitis at laparotomy.  
Patients admitted with trauma of all grades were assessed and compared with the pancreatitis group in 
terms of age, gender, racio-ethnic proportions and the prevalence of HIV. Continuous variables will be 
expressed as mean and standard deviation (no outliers) or median and interquartile range (outliers) and 
categorical variables as numbers. Students t test or the Mann-Whitney test were used to compare 
medians between groups and Pearson chi-squared (χ2) test or Fishers exact tests were used to compare 
proportions.  
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             Acute pancreatitis  
Demographic information was evaluated, a history of regular alcohol consumption was used for an 
alcohol aetiology. A gallstones aetiology was determined by transabdominal ultrasound, endoscopic 
ultrasound and endoscopic retrograde cholangiopancreatography. A drug related cause was determined 
by history.    
             Trauma  
The trauma cohort was chosen as the group which most closely mirrors the general adult population at 
admission as there is an assumption of absence of disease prior to admission.   
Consecutive patients admitted for trauma were assessed for the extent of injury and HIV status. The 
patients were recruited at the commencement of the study until 90 have been accumulated. The second 
90 patients were accumulated when half the required number of patients with acute pancreatitis had 
been recruited. The trauma cohort had their injury severity recorded.  The severity was assessed initially 
using the abbreviated injury scale (AIS). The AIS is an anatomically-based, consensus-derived, global 
severity scoring system that classifies each injury by body region (head, face, chest, abdomen, 
extremities and skin) according to its relative severity on a 6 point ordinal scale. 1 – Minor, 2 – 
Moderate, 3 – Serious, 4 – Severe, 5 – Critical and 6 – Maximal. The NISS is defined as the sum of the 
squares of the AIS scores of each of a patient's three most severe AIS injuries regardless of the body 
region in which they occur. The scores range from 0 to 75.    
3.4.2 Data collected 
1. HIV status    
2. Antiretroviral medication  
3. Duration of symptoms  
4. Amylase, urine amylase and lipase  
5. Criteria for assessing SIRS, Glasgow score, BISAP and APACHE II scores (Annexure Tables 1 to 
4)   
6. CT imaging in those with predicted severe disease or failure to improve after 1 week of admission.  
7. Complications and in hospital mortality during the same admission. Complications were defined as 
grade 1 to 5 according to the Clavien-Dindo Classification. (267)   
8. In patients with gallstone related pancreatitis cholestasis were defined as elevation of the 
cholestatic enzymes (alkaline phosphatase: > 121 U/L, gamma-glutamyl transferase:> 64 U/L and 
bilirubin >21 μmol/L), Sepsis were defined as any 2 of temperature(>38˚C), white cell(>11×1012/L) 
count and tachycardia (>90 beats/minute).   
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3.5 Data analysis 
3.5.1 Sample size 
  
The prevalence of HIV infection in the general population in KZN is 16% and 26% in the 15 – 49 year 
age group more prone to acute pancreatitis. Previous prospective trials of outcomes in acute pancreatitis 
in this region have demonstrated morbidity and mortality of 15% and 32%, and mortality of 8% and 8% 
respectively. (19, 21)   
These values were used to determine the pre-test probabilities of 10% and 20% for mortality and 
morbidity. A mortality endpoint calculation based on a hypothesized doubling of death frequency to 
20% in the HIV+ve patients in comparison to the HIV-ve patients would have required a sample sizes 
of 219 in each group. This was based on a power of 0.80, a beta set at 0.20 and alpha to detect a difference 
between the group proportions of 0.1000. The proportion in group one (HIV+ve) was assumed to be 
0.1000 under the null hypothesis and 0.2000 under the alternative hypothesis. The proportion in group 
two (HIV-ve) is 0.1000. The test statistic used was the two-sided Fisher’s Exact test. The significance 
level of the test was targeted at p=0.05.  
A recruitment target of this magnitude was not achievable given that a pancreatitis dataset to study the 
association with dyslipidaemia, took 10 years to accrue 600 patients at a busy regional hospital. Based 
on this recruitment rate it would require 6 years to accumulate 438 patients a time frame not feasible for 
the project. It was decided that a composite(morbidty and mortality) morbidity endpoint calculation 
would be more feasible. If morbidity hypothesized a doubling to 40% in the HIV+ve patients, the sample 
size of each group would be 90 to achieve 80% power to detect a difference between the group 
proportions of 0.2000. The proportion in group one (HIV+ve ) is assumed to be 0.2000 under the null 
hypothesis and 0.4000 under the alternative hypothesis. The proportion in group two (HIV-ve) is 0.2000. 
The test statistic used is the two-sided Fisher’s Exact test. The significance level of the test was targeted 
at p=0.05.   
To be feasible within 3 years the study the end point must be based on morbidity which entails assessing 
differences in combined moderate and severe disease on the composite morbidity endpoint of 
complication frequency, organ failure and mortality.    
        3.5.2 Statistical analysis  
Variables to assign groups were HIV status (HIV +ve and HIV-ve). Continuous variables were 
expressed as a mean with a standard deviation (SD) and categorical variables as numbers. The ability of 
selected severity scores to correlate with the composite severity endpoint {the frequency of local 
complications (pancreatic necrosis, pseudocysts, ascites, vascular complications, pancreatic abscess), 
organ failure and mortality during the index admission} will be evaluated by the use of 2 by 2 
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contingency tables and computing sensitivity and specificity. Receiver operating characteristic curves 
(ROC) will be calculated for the ability of each scoring system to determine disease severity. The 
predictive accuracy of each system will be assessed by determining the area under the curve (AUC) with 
95% confidence intervals. An AUC of 0.60-0.69 will be interpreted as poor, 0.70-0.79 as fair, 0.80-0.89 
as good and 0.90-1 as excellent.    
Potential outcome confounders associated with HIV infection, in particular malignancy, tuberculosis 
and opportunistic infections were assessed.   
        3.5.3 Acute pancreatitis severity assessment modalities  
The Glasgow criteria at 24 hours, CRP at 24hours, BISAP and APACHE II scores at 24 hours were used 
to predict outcomes (Annexure 1) A Glasgow score of more than 2, CRP > 150mg/l, APACHE score > 
7 and a BISAP score ≥ 2 were the cut off levels used to predict a severe outcome. Organ failure was 
assessed and defined as a score of ≥2 for at least one of the systems for determining the Marshall score 
(Table 8).   
SIRS was classified as 2 or more of the following criteria for > 48 hours: pulse > 90 beats/minute, 
temperature of <36˚C or >38˚C, white blood count <4000 or > 12000 per mm3 and respiration 
>20/minute or PCO2 < 32mmHg.    
3.5.4 Acute pancreatitis grading of severity, modified Atlanta criteria   
The pancreatitis was allocated to one of 3 grades (Annexure Table 8). Pancreatitis has two clinical 
phases, the early within the first week and the late in subsequent weeks. Severe disease in the early 
phase is based on the presence of organ failure and in the late phase on local complications or persistent 
organ failure.     
3.6 Ethics 
Ethical approval was provided by the Biomedical Ethics research committee of the University of 
Kwazulu Natal, with a bioethics number of BE222/11.  
3.7 Summary    
The study was conducted as a prospective evaluation of consecutive admissions with acute pancreatitis 
and trauma victims to 2 regional hospitals in the Durban region. The prevalence of HIV infection in 
acute pancreatitis was compared to that of a trauma cohort admitted to surgical wards. Diagnosis of 
acute pancreatitis was based on serum amylase primarily with lipase and urine amylase as the 
alternative modalities. Prognostication on the outcomes of acute pancreatitis was by the SIRS, Glasgow 
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criteria, CRP, APACHE II and BISAP scores. CD4 counts were evaluated in HIV infected patients and 
outcomes were determined in relation to a CD4 count of above or less than 200 cells/mm3. Infectious 
complications were evaluated with a microbiological spectrum and related to HIV status. The outcomes 
in HIV-ve and HIV +ve patients were compared in relation to demographic profile, aetiology, 
prognostication, morbidity and mortality during the index admission.    
 
 
 
CHAPTER 4: RESULTS  
4.1 Description and comparison of the pancreatitis and trauma cohorts   
The study was conducted from August 2013 to October 2015 and during this period 238 patients were 
admitted with acute pancreatitis and 181 consecutive trauma patients were evaluated as a comparison 
group for the prevalence of HIV infection in a hospital population. Sixty eight per cent of patients with 
pancreatitis were admitted to Addington hospital and 32% to PMMH. Pancreatitis was found in 0.01% 
of admissions to Addington hospital and in 0.002% of surgery admissions in PMMH (Table 15). In 
the pancreatitis cohort, the prevalence of HIV infection in indigenous African patients was 32(23%) 
and 6(7%) in the other racio-ethnic groups.  
One hundred and eighty one patients were admitted with trauma. The NISS ranged from 1 to 39 with 
median score of 9(IQR 4-17). Forty seven (26%) had a NISS score, that represents major trauma, 
greater than 15. The gender proportions were significantly different in the trauma and pancreatitis 
cohorts with significantly more females in the pancreatitis cohort and more males in the trauma cohort. 
The proportion of indigenous Africans was significantly higher in the trauma cohort and those of Indian 
descent significantly higher in the pancreatitis cohort. Self declared mixed and white racio-ethnic 
groups were similar (3% vs 3% and 3% vs 2%) in the two cohorts.  The prevalence of HIV infection 
in the indigenous African trauma patients was 28(18%) and 1(5%) in other racio-ethnic groups. The 
patients with pancreatitis had a 2.4 times higher prevalence of HIV and were significantly older 
{40(±12.3) vs 33(±11.8) years} than the trauma victims (p=0.001). (Table 16) A significantly higher 
number of patients in the trauma cohort (29% vs 9%) declined testing for HIV infection(p=0.001). Fifty 
nine percent of patients were on HAART in the trauma and pancreatitis cohorts. (Table 16).  
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HIV infection was more prevalent in females across all the age groups in the trauma and pancreatitis 
cohorts. In both females and males, the peak in HIV infection was in the 35-44 year age range. (Figure 
5)  
4.2 Detailed description of the entire pancreatitis cohort   
In the pancreatitis cohort 58% of the patients were male with a mean age (±SD) of 40 years (±12) and 
49% had alcohol as the aetiology.  Drugs were the only association in 24% of the patients. The 
APACHE II, SIRS and Glasgow criteria were completely assessed in 97%, 97% and 90% of patients 
respectively. The BISAP score was completely assessed in 99% and CRP in 89% of patients. CT  
assessment was performed in 34(14%) and 10(4%) had features of severe disease as defined by CTSI. 
Organ dysfunction was present in 46 patients (19%) at admission and had resolved at 48 hours in 31. 
Organ failure developed in a further 13(5%) after admission. Thirty three patients (14%) had local 
complications and 32(13%) had pancreatic ascites which was the most common complication. When 
classified according to the Clavien-Dindo system, 20(61%), 1(3%), 3(9%), 1(3%), 1(3%) and 7(21%) 
were graded 1-5 respectively. Pancreatic necrosis was found in 11(5%) of patients, none had 
established infected pancreatic necrosis, and 5 died. Six of the patients with pancreatic necrosis had 
antimicrobial therapy and sepsis was identified in the blood in 3 patients and one had a chest infection. 
Twelve (5%) of the patients with acute pancreatitis died (Table 17).   
4.3 Analysis of pancreatitis cohort based on HIV status      
Ninety (38%) of the patients with pancreatitis were HIV+ve. The proportion of 50 -74 year age group 
(28% HIV-ve vs 9% HIV+ve) was significantly higher in the HIV-ve patients (p=0.002) and the 
difference was insignificant in the other age groups. The proportion of female patients (53% vs 35%) 
(p=0.02) and indigenous Africans (93% vs 50%) (p<0.001) were significantly higher in the HIV+ve 
patients than in the HIV-ve patients.  In 22(9%) patients the HIV status was not known as patients 
declined testing for HIV infection (Table 18).  
The assessment of aetiological patterns revealed that the prevalence of gallstone (27% vs 30%) and 
alcohol (41% vs 52%) aetiologies were similar between HIV+ve and HIV-ve patients and a drug related 
aetiology was more prevalent in HIV+ve related pancreatitis (24% vs 0%). Lamivudine, Isoniazid and 
Trimethoprim-Sulfamethoxazole were the drugs associated with pancreatitis in the HIV+ve group. One 
HIV+ve patient had Kaposi sarcoma of the ampulla of Vater as a possible cause of the acute 
pancreatitis. Diabetes (14% vs 3%) (p=0.026) and hypertension (22% vs 8%) (p=0.015) were more 
prevalent in HIV-ve patients. Amylase was measured in 234 (98%) patients, lipase in 169(71%) 
patients and urine amylase in 133(56%). There was no difference in the mean values of the diagnostic 
tests in HIV+ve and HIV-ve patients. Two patients in the HIV+ve patients had normal pancreatic 
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enzymes and the diagnosis was made at laparotomy and in 2 HIV-ve patients the diagnosis was made 
by CT imaging (Table 19).    
Serum amylase as the primary diagnostic enzyme supported a diagnosis of acute pancreatitis in 
179(75%) of the patients. In the 55(25%) not diagnosed by serum amylase, 33(60%) were diagnosed 
with aid of urinary amylase and the remaining 22 were diagnosed using serum lipase. (Table 20) There 
was no difference in the patients primarily diagnosed with serum amylase in the HIV-ve (79%) and 
HIV+ve (71%) patients.  
Fifty three (59%) of HIV+ve patients were on HAART. Their treatment with 1st line drug regimens are 
detailed in Table 21. The mean CD4 count(±SD) was 335 cells/mm3(±246) and 27(30%) had a CD4 
count less than 200 cells/mm3. There was no difference (p=0.46) in the mean CD4 counts of patients 
not receiving HAART 298 cells/mm3 (±301) and those receiving  HAART 348 cells/mm3 (±197).  
4.4 Disease severity assessment in HIV+ve and HIV-ve pancreatitis 
Subsequent analysis of scoring systems were performed on the ability to predict the composite 
endpoint, organ failure (persistent beyond 48 hours), local complications and mortality. In predicting 
outcomes, the scorings systems were computed with and without age and the mean scores compared in 
the HIV-ve and HIV+ve patients. There was a significantly greater proportion of HIV+ve patients with 
an APACHE II score ≥ 8(62% vs 31%) (p = <0.001). A BISAP score >2 was marginally higher (45% 
vs 38%) in HIV+ve patients (p = 0.041).  CRP, organ failure and the Glasgow score were similar in the 
2 groups of patients. CT assessment was performed with similar frequency in the 2 groups (13% vs 
14%). (Table 22)  
There was a significantly higher proportion of HIV-ve (64% vs 46%) patients with positive SIRS 
criteria. None of the HIV+ve patients had three or four SIRS criteria (Table 27). The evaluation of 
severity assessment parameters is detailed in Tables 28 and 29 and Figures 7-10. SIRS and CRP were 
the least effective (AUC) in predicting a moderate/severe outcome in all the pancreatitis patients with 
AUC of 0.66 and 0.68 respectively. BISAP, Glasgow and the APACHE systems were more effective 
with AUC between 0.71 and 0.80. There was an improvement in the performance of the BISAP and 
Glasgow scores when age was omitted in computing the scores (BISAP 2 and Glasgow 2). The same 
was not observed with the APACHE II score (Table 28).  Pairwise comparisons assessed the closeness 
of two scoring systems and these were interpreted according to the following values: 0.3=weak, 
0.5=moderate and 0.7=strong. The analysis is shown in Table 29 and there was a strong correlation 
between BISAP, Glasgow and APACHE II when these were paired with each other whereas SIRS and 
CRP had a strong association between the two.  
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When HIV-ve patients were assessed all the scoring systems other than SIRS had performances that 
exceeded an AUC of 0.7(Figure. 7). All the scoring systems showed marginal improvement when age 
was omitted from the computation. The APACHE II system was the best predictor of poor outcome 
(Table 30).  
The APACHE II was also the best predictor of a severe outcome in HIV+ve patients with AUC of 
0.89(Fig. 8). CRP was a poor predictor in HIV+ve patients with AUC of 0.59. In HIV+ve patients 
BISAP, Glasgow and APACHE II scores had AUC exceeding 0.7 and all improved when age was 
omitted (Table 30).   
 
4.5 Comparison of morbidity and mortality in HIV +ve and HIV -ve patients 
Assessment of outcomes revealed that there was no difference in the organ failure (17% vs 19%), 
morbidity (13% vs 14%), hospital stay (10 ± 8 vs 10 ±8) and mortality rates between the HIV-ve and 
HIV+ve patients (6% vs 4%) (Table 23 and 24).  Sepsis was found in 20(8%) of the patients, 16(13%) 
were HIV-ve and 4(4.4%) HIV+ve (Table 25). Most 16(80%) of the infections were diagnosed within 
2 weeks. The one tuberculosis and one CMV infection were found in two different HIV+ve patients. 
Sepsis of pancreatic necrosis was not demonstrated. Three of the patients with sepsis died, one was 
HIV+ve with tuberculosis and the other two were HIV-ve patients.   
4.6 Outcomes in gallstone related pancreatitis with and without HIV infection 
Twenty four (27%) of HIV+ve patients and 38(30%) of HIV-ve patients had gallstone related 
pancreatitis (Table 26). There was no difference in the gender distribution between the HIV+ve and 
HIV-ve patients in this sub-group. The HIV+ve patients were significantly younger with a mean age 
(±SD) of 35 years (±8.3) vs 45 years (±15) (p=0.003). CRP values were insignificantly lower in the 
HIV+ve patients (25% vs 18%) and the APACHE II ≥ 8 was significantly higher in HIV+ve patients 
(79% vs 7%)(p<0.001). More HIV+ve patients had cholestasis,{22(92%) vs 26(68%)} p=0.059 and 
more had ERCP, {10(42% vs 4(11 %)} p=0.004. In patients with gallstone pancreatitis, there was a 
trend in the HIV+ve compared to the HIV-ve patients towards increased morbidity (17% vs 5%) and 
mortality (8% vs 2%).  
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4.7 Asessment of disease severity in patients with CD4 counts less than or greater than 200 
cells/mm3 
Evaluation based on CD4 counts in HIV+ve patients revealed that significantly more females, 31(78%) 
than males, 15(47%)(p=0.01) had CD4 counts greater than 200 cells/mm3. The age, length of hospital 
stay and severe outcomes did not differ between the groups based on the CD4 cut off level (Table 31).   
SIRS and CRP scores were of no value in predicting severe disease in patients with CD4 counts < 200 
cells/mm3 with AUC of 0.51 and 0.46 respectively. In patients with CD4 counts > 200 cells/mm3 CRP 
had an AUC of 0.73 and SIRS 0.83. The BISAP score with or without the age factor fared poorly in 
those with CD4 counts <200 cells/mm3 and was best at AUC of 0.90 in predicting severe disease in 
those with CD4 counts > 200 cells/mm3. The Glasgow and APACHE II scores performed similarly in 
the 2 groups with AUC greater than 0.8 (Figures 9 and 10). SIRS and BISAP scores are affected by 
the significant number of patients with a score of zero having a severe outcome (Table 32). There is a 
similar trend of improved performance of the scores when age is excluded.   
4.8 Factors associated with severe disease in HIV related pancreatitis 
In the pancreatitis cohort of 238 patients, 29 (12%) had severe forms of the disease. Most of the severe 
disease was found in the 31- 40 year age group. There was no trend toward an increasing severity with 
age and three (10%) episodes of severe disease were in the patients > 60 years old (Figure 6).  In HIV 
related pancreatitis there was no difference in the age of those with mild, 37 (SD±8) and severe disease, 
35 (SD±9). The number of patients with CD4 counts less than 200 cells/mm3 also did not differ between 
mild (20%) and severe disease forms (26%). The number of patients on HAART was also similar in 
the two groups (57% vs 62%). Of the haematological and biochemical tests performed in the evaluation 
of acute pancreatitis, urea and creatinine values of > 7.1 mmol/l (p = 0.000) and > 90 umol/l (p = 0.004) 
respectively were associated with severe disease in HIV related pancreatitis. Although there was no 
difference in morbidity and mortality between HIV+ve and HIV-ve pancreatitis, the mortality rate 
differed between those with CD4 counts less than 200 cells/mm3(15%) and those with CD4 counts 
more than 200 cells/mm3(2%) (p=0.035). 
4.9  Summary  
These results demonstrate a higher prevalence of HIV+ve patients in the pancreatitis cohort than in the 
trauma cohort. The patients with acute pancreatitis were significantly older than the trauma patients 
and there were significantly more females in the acute pancreatitis cohort. Serum amylase was not 
adequate for supporting the diagnosis of acute pancreatitis in this cohort and required the addition of 
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urine amylase and serum lipase. The rate of infection was not higher in the HIV+ve cohort but did 
include tuberculosis and Cytomegalvirus. In gallstone pancreatitis associated with HIV infection, 
cholestasis was more frequent and there was a trend toward an increased performance of ERCP. The 
currently widely used markers of severe disease are applicable to HIV+ve patients whose CD4 counts 
are not < 200 cells/mm3 and the Glasgow and APACHE II are specifically useful in patients with a 
CD4 count less than 200 cells/mm3. Despite these differences morbidity is similar in HIV+ve and HIV-
ve patients with acute pancreatitis in this cohort and between patients with CD4 counts less than or 
greater than 200. Most of the mortality is in patients with CD4 counts less than 200 cells/mm3. 
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CHAPTER 5: DISCUSSION  
 
5.1 HIV prevalence in acute pancreatitis and trauma cohorts 
Previous studies on acute pancreatitis in which HIV infection was not routinely tested at a regional 
hospital setting in Durban demonstrated that 5% in 2008 and 11% in 2012 of patients diagnosed with 
acute pancreatitis were associated with HIV infection. (17, 19) The 38% prevalence in this study 
represents a 3.4 fold increase over the 2012 reported prevalence. To put this in context we used a trauma 
cohort as a comparator for the prevalence of HIV infection in the hospital population. The trauma 
cohort with a median NISS score of 9(IQR 4-17) and 26% having a score greater than 15 was 
considered generally representative of the range of trauma severity as in comparison to another 
institution in the Kwazulu Natal (KZN) Province which had a similar distribution of injury severity 
with a NISS of 12(IQR 6.7-23.2) with 25% having a score greater than 15. (276) The prevalence of 
HIV infection was 2.4 times higher in patients with acute pancreatitis than in those admitted with 
trauma. The HIV infection rate in the trauma cohort of 16% is consistent with the HIV+ve prevalence 
recently reported as 17% in a KZN Province population based study (25) and less than half the 
prevalence in the acute pancreatitis cohort. The prevalence of HIV infection in the indigenous African 
trauma patients was 28(18%) and 1(5%) in other racio-ethnic groups. In the pancreatitis cohort, the 
prevalence of HIV infection in indigenous African patients was 32(23%) and 6(7%) in other racio-
ethnic groups. When the trauma and pancreatitis cohorts, matched for age, gender and ethnicity were 
compared, the HIV infection prevalence increased to 53% in the acute pancreatitis cohort and to 23% 
in the trauma cohort.   
There was a difference in the admissions with acute pancreatitis in the 2 hospitals. The hospital of 
predominant indigenous African patients had a 5-fold lower prevalence of acute pancreatitis than the 
hospital with a higher Indian ethnic group admission rate (Table 20). The 42% female gender 
distribution in the pancreatitis cohort is lower than other series where females accounted for 49% and 
54% of acute pancreatitis admissions. (11, 98) This may be as a result of the lower contribution of 
gallstones as an aetiology association in this study where gallstones and alcohol accounted for 28% and 
48% of cases respectively and differed from international studies where gallstones are predominant (34 
- 69%) and alcohol has a lesser frequency of 7 - 33 %. (12-15) The mean age of 40 years in this cohort 
is also significantly lower than the majority of studies reporting a mean age range of 51-56 years. (2, 
9, 12, 277)   
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5.2 Diagnosis and severity assessment tools in HIV related pancreatitis 
Despite previous reports of asymptomatic elevation in serum amylase in HIV infected patients, the 
serum amylase was equally effective in diagnosisng acute pancreatitis in HIV-ve and HIV+ve patients. 
(23, 26)  
The number of HIV+ve patients in both groups receiving HAART(59%) is nearly double the national 
figure in 2012 of 31%. (25) This increased use of HAART may partially explain the increased 
prevalence of HIV infection in the pancreatitis cohort as the treatment of HIV infection includes 
prophylactic therapy with Isoniazid and Trimethoprim-Sulfamethoxazole, both of which are implicated 
in drug induced pancreatitis. This is supported by the report by Trivedi where drug induced acute 
pancreatitis was more prevalent(as high as 40%) in the HIV infected population as opposed to the 
general population(2%). (278) In this study 24% of patients had drugs as the most probable aetiological 
association in HIV+ve patients whereas the study by Gan had drugs as a possible cause in 46% of 
patients. (37)  The drug combinations are listed in Table 21 and 34% were treated with Lamivudine 
and 59% with Trimethoprim Sulfamethoxazole. Among the antimicrobials commonly used in patients 
with HIV infection, Sulfamethoxazole, Isoniazid, Trimethoprim-Sulfamethoxazole and Rifampicin 
have been linked to acute pancreatitis. The appropriate response when drugs are considered to be a 
cause of pancreatitis depends on the severity of the attack. Patients recovering from a mild attack of  
acute pancreatitis require alternative drug therapy it there are recurrent attacks. Patients surviving a 
severe attack will require alternative therapy if the drug therapy (type Ia likelihood see annexure) is 
perceived as the cause of the pancreatitis.  
Drugs however may not be the sole explanation for the increased prevalence of pancreatitis in HIV+ve 
patients as in some of the initial reports on HIV+ve patients reporting a high prevalence of acute 
pancreatitis, patients were not on therapy with HAART and had low CD4 counts. These observations 
are supported by the findings reported by Dowell where pancreatitis was associated with advanced 
disease (AIDS) (279) and in the study by Trivedi where 84% of patients with HIV related pancreatitis 
had AIDS(CD4 counts < 200 cells/mm3). (278) In another American study 57% had CD4 counts < 200 
cells/mm3 with a median count of 160 cells/mm3. The majority (80) were African-American and female 
(OR 2.58; 95% CI {1.58, 4.24} and 55% were on HAART. (280) The trend toward a low CD4 count 
and a racio-enthnic bias was also seen in the study by Parithivel where 89% had CD4 counts below 
200 cells/mm³ and 61% were African American. (42) The findings reported here show a median CD4 
count of 298cells/mm³ (±231) and a CD4 count of <200 cells/mm³ in 22%. This improvement in CD4 
counts over these previous studies is most likely due to the high number of patients on HAART. 
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 As eluded to in the introduction an infective cause of acute pancreatitis is difficult to prove. In this 
study Cytomegalovirus was the only infection to which a probable cause could be attributed. In HIV-
ve patients the spectrum of infecting organisms is similar to previous studies with Gram positive and 
negative bacteria and fungal organisms. (195, 196) In HIV+ve patients these included Cytomegalovirus 
and Tuberculosis. The patient with Tuberculosis died. In high HIV prevalent environments it may be 
prudent to routinely test for HIV infection in patients with severe acute pancreatitis as this may trigger 
a search for treatable opportunistic infections.    
The patients with HIV+ve gallstone pancreatitis were younger than HIV-ve patients (35 ±8 vs 45 ±15). 
The age difference between HIV-ve and HIV+ve patients with gallstone pancreatitis has not been 
previously reported. More of the HIV+ve patients had cholestasis (92% vs 68%) but the rate of 
cholangitis was similar (29% vs 21%). Although jaundice (bilirubin >51umol/l) was found with similar 
frequency in HIV+ve and HIV-ve patients with gallstone related pancreatitis (33% vs 26%), the rate of 
ERCP was higher (42% vs 11%) in HIV+ve patients as was  the yield of bile duct stones (25% vs 8%) 
(Table 27).   
Ideally, prognostication in acute pancreatitis should be feasible at admission to facilitate early 
intervention in terms of specific measures and admission to high dependency areas for those with severe 
disease. The Ranson and Glasgow criteria were validated for use at 48 hours after admission in a HIV-
ve population. (281) The complications of acute pancreatitis and organ failure are related to time from 
onset of symptoms and time from admission to health care. The effectiveness of the different systems 
in predicting severe outcomes may be limited by these temporal relationships. In this study prognostic 
scores were computed within 24hours of admission as the symptom interval was variable and difficult 
to use. The Ranson criteria were therefore not computed and the Glasgow criteria were used at 24 
hours.  
The appropriate timing of the use of CRP in severity assessment of acute pancreatitis is controversial. 
CRP is synthesized in the hepatocytes as a response to cytokine stimulation and may therefore lag 
behind the initial SIRS. The CRP after 24 hours was superior to the CRP at admission with an area 
under the curve of 0.68 and 0.52 respectively both of which are poor levels of accuracy. (41) In the 
study by Lawson CRP was more useful if the assessment was delayed to 48 hours in predicting severe 
acute pancreatitis. (245)   
In HIV+ve patients, CRP levels were found to negatively correlate with CD4 counts in 119 HIV+ve 
patients and were the highest in those with CD4 counts less than 200 cells/mm3. (282) In an American 
study over 5 years the CRP level was ≥3mg/L in 34% of 922 HIV+ve patients enrolled in the study of 
Fat Redistribution and Metabolic Change in HIV infection (FRAM). The mortality rate in patients with 
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CRP >3 mg/L, 1–3 mg/L and CRP <1 mg/L was 19%, 14% and 7% respectively. (283) These two 
reports suggested that CRP is elevated in HIV+ve patients without pancreatitis and questions the 
suitability of CRP in severity assessment of acute pancreatitis HIV+ve patients. I found that the benefit 
of CRP is dependent on the HIV status as well as the CD4 count as CRP at 24 hours was more effective 
in predicting severe disease in HIV-ve patients (AUC= 0.75) than in HIV+ve patients (AUC= 0.59) , 
and in  patients with a CD4 count of ≥ 200 cells/mm3 (AUC=0.73) than in patients with CD4 counts 
below 200 cells/mm3 (AUC= 0.46).   
The BISAP scoring system was derived from 17,992 cases of acute pancreatitis in 212 hospitals in the 
period 2000-2001 and validated from 18,256 acute pancreatitis cases from 177 hospitals in 2004-2005. 
The AUC of BISAP was 0.82 and 0.83 for APACHE II system. This is a better outcome than the present 
study where the BISAP system performed with AUC of 0.73, 0.71 and 0.74 for the entire cohort, HIV-
ve and HIV+ve patients respectively.   
The Glasgow score was useful in HIV+ve(AUC = 0.78) and HIV-ve patients(AUC=0.72) and better in 
patients with CD4 count < 200 cells/mm3(AUC=0.83) and CD4 count ≥ 200 cells/mm3(AUC=0.81).  
The APACHE II score was positive for severe outcomes in 62% (≥8) of HIV+ve patients and it 
predicted a severe outcome in both HIV-ve and HIV+ve patients with AUC of >0.8 and in both CD4 
count ranges with AUC > 0.80. The APACHE II score was the best predictor of poor outcome in this 
study.  
Previous studies which assessed these prognostication systems did not demonstrate equivalent results 
to this study. In Cappell’s study, 61% had CD4 counts less than 200 cells/mm3 and the Glasgow and 
Ransons criteria were poor predictors of a severe outcome with sensitivities and specificities lower than 
50%. The APACHE II score was a better prognosticator with a sensitivity and specificity of 73% and 
68% respectively. (31) In a previous American report, the majority of patients (89%) had CD4 counts 
less than 200 cells/mm3 and criteria applicable in the APACHE II and Ranson’s criteria were unhelpful 
in predicting a severe outcome. They had a mortality rate of 32% (42). In a similar setting, 84% of 
patients had CD4 counts less than 200 cells/mm3 and the Ranson, Glasgow and APACHE II scores had 
accuracies of 48%, 69% and 75% respectively.(37) 
In the present study when age was removed from the scoring systems there was a marginal 
improvement in the ability to predict a moderate to severe disease outcome. These improvements were 
evident in HIV-ve and HIV+ve patients. 
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5.3 Morbidity and mortality rates in HIV related pancreatitis   
The overall mortality rate of 5% does not differ from other studies where the rate was 6%-9%. (5, 284) 
Mortality was not associated with advancing age and the mean age of pancreatitis in HIV+ve and HIV-
ve patients is a decade lower than that reported in western studies. This younger patient population is 
part of the explanation for the low mortality.   
The mortality rate in HIV+ve patients in this study (6%) is less than the 10% reported by Gan (37) 
They did not find a difference in the mortality between HIV+ve patients and HIV-ve historical controls. 
Although the current cohort was not sufficiently powered to detect a difference in mortality based on 
HIV status, there are trends around mortality and CD4 counts which may partially explain the lower 
than expected morbidity and mortality.  In two American studies the mortality rate was 5.9% (286) and 
32% (46) in HIV+ve patients with sample sizes of 5970 and 54 patients respectively. The differences 
in mortality in these studies can be partially explained by the 58% vs 89% rate of CD4 count < 200 
cells/mm3 and the pre-existing liver and renal disease in the cohort with a larger mortality rate. In the 
present study where 29% of patients had a CD4 < 200 cells/mm3, 4 of the 5 HIV+ve patients who died 
had CD4 < 200 cells/mm3. The mortality of 15% in those with CD4 counts <200 cells/mm3 was greater 
than the 2% in those patients with CD4 counts > 200 cells/mm3(p=0.035). This suggests that treatment 
with HAART and keeping CD4 counts above 200 cells/mm3 may reduce mortality in HIV associated 
pancreatitis. 
5.4 Factors associated with morbidty and mortality in HIV related pancreatitis 
The age was similar in those with mild and severe HIV related pancreatitis. Although the CD4 counts 
were similar in those with mild and severe HIV related pancreatitis the majority of those who died in 
this group had CD4 counts less than 200 cells/mm3. A urea of more than 7.1 mmol/l(44% vs 6%)(p = 
0.000) and a creatinine value more than 90 umol/l(44% vs 16%)(p = 0.004) were also associated with 
severe HIV related pancreatitis. One of the patients with an opportunistic infection, Tuberculosis, died.  
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Chapter 6: Conclusions 
  
 
6.1 Introduction  
In relation to the primary hypothesis we can conclude that HIV infection is more prevalent in a 
pancreatitis cohort than in a trauma cohort or the general population in this region of South Africa. The 
spectrum of aetiologies is similar except for a drug aetiology being more common in the HIV+ve cohort 
and the only malignant cause was in the HIV+ve group of patients. The study partially refutes the 
hypothesis that the scoring systems are not effective in predicting severe disease in HIV related 
pancreatitis as the APACHE II score was effective in predicting severe disease in the HIV-ve and 
HIV+ve patients with acute pancreatitis. The other scoring systems were not as accurate in patients with 
CD4 counts < 200 cells/mm3. This study has also refuted the hypothesis that outcomes are poorer in 
HIV associated pancreatitis as there was no difference in moderate to severe pancreatitis between the 
two groups of patients.  
6.2 Limitations  
Demonstrating differences in disease severity between HIV-ve and HIV+ve acute pancreatitis will be 
unlikely, given the low levels of morbidity and especially mortality demonstrated in this study, unless 
a much larger cohort from multiple centres can be  recruited. These low levels of morbidity are at least 
partly attributable to the younger patient profile of this cohort as compared to reports from international 
series (15, 102). This is more pertinent as advancing age was not associated with poorer outcomes and 
that the HIV+ve patients were younger than HIV-ve patients. The second explanation is the proportion 
of patients with a CD4 count of less than 200 cells/mm3 is lower than previous studies conducted prior 
to the advent of HAART when most patients had low CD4 counts. This is pertinent as the mortality 
rate in the current study was seven times higher in those with a low CD4 count.  
6.3 Significance and recommendations 
In an environment where serum amylase remains the primary biochemical marker of acute pancreatitis, 
serum amylase was sufficient in establishing the diagnosis in only 75% of patients and in the remaining 
patients, confirmation of the diagnosis required urine amylase or lipase. In four patients imaging by CT  
and laparotomy were required to confirm the diagnosis. This necessitates a shift to the use of serum 
lipase which has been demonstrated to be the preferred biochemical confirmatory test for acute 
pancreatitis in a number of studies.  
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When all categories of patients were considered (HIV-ve, HIV+ve and CD4 < or > 200 cells/mm3), the 
APACHE II scoring system was the most accurate in predicting a severe outcome and the Glasgow 
systems can be used at 24 hours in a South African context in both HIV-ve and HIV+ patients with a 
fair AUC. 
As the spectrum of infecting organisms in HIV+ve patients included CMV and tuberculosis which are 
not usually associated with septic complications in acute pancreatitis, it is prudent to test for HIV 
infection in areas of high HIV prevalence as the presence of HIV infection in acute pancreatitis will be 
a trigger to seek opportunistic infections.   
In HIV associated pancreatitis without an attributable cause the further elucidation of the aetio-
pathogenesis lies between the HIV disease itself, the drugs used to restore immune competency or 
prevent opportunist infection and opportunist infections themselves. Temporal association with the 
drugs is the best predictor of causality but this is often absent. Similarly, without direct sampling of the 
pancreas by invasive means, ERP or EUS it is difficult to prove that the infective causes demonstrated 
by post mortem studies are present in vivo. 
The sample size calculation based on the older literature on the subject resulted in an overestimation of 
the complications and mortality rates utilized in the sample size calculation for this study. 
6.4 Conclusion 
This study however does provide a reference point for future studies in sub -Saharan Africa and reveals 
that outcomes are similar in pancreatitis in HIV-ve patients and HIV+ve patients and that in HIV+ve 
patients mortality is related to their CD4 count. As there are advances in the therapy of HIV infection 
and a decline in the numbers of those with CD4 counts less than 200 cells/mm3, the mortality in HIV 
related pancreatitis is likely to approach that in HIV negative patients. This finding can assist in 
planning future research and further investigation into the relationship between acute pancreatitis and 
HIV infection in high HIV infected areas.         
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TABLES INTRODUCTION  
Table 1: Acute pancreatitis: spectrum of aetiologies   
 
 
 
 
 
 
 
 
 
 
 
  
Causes in 80%  
Alcohol 
Biliary  
  
 Examples 
  
Gallstones   
Microlithiasis 
Causes in 20%  
Idiopathic  
Metabolic  
  
  
Hypertriglyceridaemia  
Hypercalcaemia  
Obstructive  
  
Periampullary tumours  
Intraduct Papillary Mucinous Neoplasm  
Drugs  
  
Azathioprine, Didanosine, Isoniazid, 
Trimethoprim-Sulfamethoxazole, 
Rifampicin, Isoniazid,    
ERCP  
Post-operative 
Congenital  
  
  
 Pancreas divisum  
Annular pancreas  
Long common channel  
Sphincter of Oddi dysfunction  
Autoimmune 
Hereditary 
Autoimmune type 2, familial 
pancreatitis 
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Table 2: Variations in the frequency of the main aetiologies of acute pancreatitis by country   
Author  Year  Origin  Number  Alcohol  Gallstones  Idiopathic  HIV  
    Per cent 
International                
Thomson 2  1987  Scotland  378  25  75  NS  NS  
Mann3  1994  England  631  30  29  NS  NS  
Lowham 4  1999  England  105  25  48  23  NS  
Gloor 5  2001  Switzerland  106  35  45  20  NS  
Appelros 6 2001  Sweden  883  32  38  23  NS  
Ashley 7  2001  USA  99  26  40  NS  NS  
Ricci 8  2002  Italy  125  33  76  0  NS  
Mofidi 9 2007  Scotland  759  33  47  13  NS  
Bai 10  2007  China  1976  9  59  25  NS  
Carnovale 11  2005  Italy  1150  7  68  12  NS  
Frey 12 2006  USA  70 231  20  33  37  NS  
Dellinger 13  2007  Multicentre  100  44  34  NS  NS  
Bumbasirevic 14  2009  Serbia  110  0  36  20  NS  
South African                
John 15  1997  S. Africa  136  83  7  7  NS  
Funnell 16  1993  S. Africa  99  74  14  7  NS  
Anderson 17  2008  S. Africa  322  62  14  7  5  
Moolla 18 2013  S. Africa  464  59  17  4  11  
Anderson 19  2017  S. Africa  627  61  19  NS  17  
NS = Not stated                 
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Table 3: Diagnostic accuracy of amylase and lipase in acute pancreatitis  
Study Enzyme Cut-off level Sens Spec PPV NPV PLR PTP Accuracy ROC 
Steinberg 45 Amylase 225U/l 95 89 NS NS NS NS NS NS 
 Amylase 600U/L 95 86 NS NS NS NS NS NS 
 Lipase 75U/L 87 90 NS NS NS NS NS NS 
Ventrucci 46 Lipase latex test 200 pg/L 83 86 42 98 NS NS NS NS 
 Lipase ELISA 62 +g/L 92 85 42 99 NS NS NS NS 
 Total amylase 377 U/L 92 78 36 99 NS NS NS NS 
Kylänpää-Bäck 47 Lipase 200U/L 79 88 49 97 7 24 NS NS 
  600U/L 55 99 84 94 55 45 NS NS 
Chen 48 Lipase 570U/L 94 93 90 96 NS NS 93 NS 
 Amylase 570U/L 79 95 91 87 NS NS 89 NS 
Sáez 49 Lipase >180 U/L 84 86 93 72 6 93 NS NS 
 Amylase >330 U/L 74 86 93 59 5 92 NS NS 
Smith 50 pancreatic lipase NS 90 93 NS NS NS NS NS 95 
 serum amylase NS 79 93 NS NS NS NS NS 91 
Wilson 51 Lipase (all) >570 U/L 100 99 97 100 NS NS 99 NS 
 Amylase >324 U/L 63 99 95 93 NS NS 94 NS 
 Lipase (<48hours) >570 U/L 100 99 96 100 NS NS 99 NS 
 Amylase >324 U/L 63 99 94 94 NS NS 94 NS 
 Lipase (>48hours) >570 U/L 100 100 100 100 NS NS 100 NS 
 Amylase >324 U/L 67 100 100 99 NS NS 99 NS 
Petrov 52 Lipase >180U/L 77 95 89 87 NS NS NS 96 
 Amylase >300U/L 92 94 89 95 NS NS NS 91 
Gomez 53 Amylase NS 79 99 NS NS NS NS NS NS 
 Lipase NS 97 99 NS NS NS NS NS NS 
Bang 54 FPL/total  lipase 0.0027 83 64 NS NS 2 NS NS 72 
 Hepatic lipase NS NS NS NS NS NS NS NS 67 
 Pancreatic lipase  NS NS NS NS NS NS NS NS 65 
 Lipoprotein lipase NS NS NS NS NS NS NS NS 62 
 Endothelial lipase NS NS NS NS NS NS NS NS 56 
 Serum lipase  NS NS NS NS NS NS NS NS 58 
 Serum amylase  NS NS NS NS NS NS NS NS 54 
FPL: fraction pancreatic lipase. NS: not stated.TAP: Trypsinogen activating peptide 
NPV- negative predictive value PLR- positive likelihood ratio PTP- Posttest probability 
ROC- Receiver operating characteristic Sens: sensitivity Spec: specificity 
PPV- positive predictive value 
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Table 4: Diagnostic accuracy of isoenzymes and other enzymes in acute pancreatitis    
Study Year  Enzyme Cut off level Sens Spec PPV NPV PLR PTP 
Steinberg 46 1985 Serum Trypsinogen  85g/ml 97 83 NS NS NS NS 
  Pancreatic amylase 375U/L 92 85 NS NS NS NS 
Ventrucci 47 1986 Pancreatic-Isoamylase 220 U/L 100 84 46 100 NS NS 
Kylänpää-Bäck 48 2001 Urine trypsinogen-2  NS 93 92 NS 99 NS NS 
Sáez 49 2005 TAP urine NS 69 40 73 35 1 72 
  Urine Trypsinogen-2 NS 69 86 91 54 5 92 
Chen 50 2005 Urine Trypsinogen-2  50 mg/L 97 86 81 92 NS NS 
Wilson 52 2005 Elastase 2.5 g/mL 80 96 80 96 NS NS 
  Elastase(<48hours) 2.5 g/mL 75 97 78 96 NS NS 
  Elastase(>48hours) 2.5 g/mL 100 96 55 100 NS NS 
TAP: Trypsinogen activating peptide 
Sens: sensitivity Spec: specificity, PTP: pretest probablity; PTP: Posttest probability 
PPV: positive predictive value, NPV: negative predictive value 
PLR: positive likelihood ratio, NS: not stated 
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Table 5: Markers of a biliary aetiology   
Series Diagnostic standard Year Biochemical marker or 
imaging procedure 
Timing sens spec PPV NPV 
Goodman 78 AUS, ERCP, surgery 1985 1 or more +ve  admission 73 94 97 57 
   ALP > 225iu/l ALT 
>75iu/l,BR>40umols/l 
     
Davidson 79 NS 1988 ALT 48 hours 75 74 78 69 
   ALT + ALP+ bilirubin  74 78 81 70 
   ALT + ALP + gender+ age + 
amylase 
 62 80 80 62 
Sugiyama 80 AUS, CT scan, 1998 ERCP 24-72 
hours  
100 100 NS NS 
 BR>41.04 umol/l, 
ALT>60u/l 
 EUS  100 100 NS NS 
Chak 81 AUS, ERCP, surgery 1999 EUS <72 91 100 100 95 
Ammori 82 AUS, EUS,  2003 AUS  86 1 1 80 
 postmortem  ALT≥80 iu/L  91 1 1 86 
   AUS+LFT  98 1 1 96 
Liu 83 Surgey, IOC, ERCP 2005 EUS <24 100 NS NS NS 
Levy 84 EUS 2005 Age >50  73 65 NS NS 
   ALT>2×ULN  74 84 NS NS 
Anderson 85 AUS, CT scan or MRI 2010 Female  48 hours 58 54 59 52 
   Age > 50 years   67 49 60 56 
   ALT > 100 units/l  66 79 79 67 
   ALT > 150 units/l   59 84 81 64 
Gungor 86 MRCP, ERCP and IOC 2010 ALP > 246 U/L ? 62 60 81 38 
   BR>20.53 umol/l  65 67 84 43 
   Direct bilirubin>3.42 umol/l  60 65 82 38 
   Amylase>970u/l  61 57 79 36 
   Lipase>1400u/l  61 60 80 38 
Moolla 18 AUS 2013 Amylase (1,000 U/l, normal: 24 hours 63 75 35 90 
   ALT (150 U/l)   51 97 80 90 
   Combined  36 97 85 87 
AUS: Transabdominal ultrasound, EUS: Endoscopic ultrasound, MRI: Magnetic resonant imaging, ERCP: 
Endoscopic retrograde cholangiopancreatography, Intraoperative cholangiogram: IOC, Bilirubin : BR, Magnetic 
resonce cholangiopancreatography: MRCP, Computerised Tomography: CT,  ALT:  
Alanine transaminase,  
ULN:Upper limit of normal, ALP: Alkaline phosphatase, LFT: Liver function test, AST: Aspartate 
transaminase, Sens: sensitivity, Spec: specificity, PPV: positive predictive value, NPV: negative p 
\redictive value 
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Table 6: Parameters to define organ failure in the modified Marshall score  
Organ system Score 
 0 1 2 3 4 
Respiratory  >400 301-400 201-300 101-200 ≤101 
(PaO2/FiO2)      
Renal       
(serum creatinine, µmol/l) <134 134-169 170-310 311-439 >439 
Cardiovascular      
Systolic blood pressure,  
(mmHg) 
>90 <90,fluid 
responsive 
<90, not fluid 
responsive 
<90, pH <7.3 <90, pH <7.2 
 
Calculation for FiO2 in non-ventilated patients 
Oxygen (l/min) FiO2 
Room air 21 
2 25 
4 30 
6 to 8 40 
9 to 10 50 
 
Criteria for organ failure: Score of >2 for each organ 
 
  
 
Table 7: Variation in mortality related to age in acute pancreatitis    
Age Mortality per 100,000 
<30 1.0 
30-40 1.4 
40-50 2.9 
50-60 4.4 
60-70 8.6 
>70 18.8 
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Table 8a: Series of markers of disease severity in acute pancreatitis 1993-2000   
Study Year No Timing  Endpoints Test and cut-off Sen Spec PPV NPV Accuracy AUC 
Gudgeon 38 1990 55 Day 0 Complications TAP≥ 2nmol/l 80 90 NS NS NS NS 
    
Death CRP≥ 20mg/l 53 55 NS NS NS NS 
   
24 hrs 
 
TAP≥2nmol/l 80 85 NS NS NS NS      
CRP≥100mg/l 60 75 NS NS NS NS 
      48hrs   Glasgow  60 93 NS NS NS NS    
5 days 
 
CRP≥200mg/l 73 75 NS NS NS NS 
Dominguez-
Munoz 39  
1993 182 24-48 
hrs 
Complications: local 
and systemic 
Glasgow 48hrs 84 77 NS NS 78 NS 
     
APACHE II 
24hrs 
70 79 NS NS 77 NS 
     
APACHE II 
48hrs 
69 77 NS NS 76 NS 
     
SAPS 24hrs 67 79 NS NS 77 NS      
SAPS 48hrs 73 69 NS NS 70 NS 
Tenner 40 1997 139 48 hrs Pancreatic necrosis, 
organ failure 
TAP 5ng/ml 100 75 45 100 NS NS 
     
TAP 10ng/ml 100 85 60 100 NS NS 
     
TAP 15ng/ml 89 95 80 98 NS NS      
TAP20ng/ml 67 95 75 94 NS NS 
 
Neoptolemos41 
2000 246 24hrs Local or systemic 
complications 
TAP>35nmol/l 68 74 NS NS 73 NS 
    
Death CRP>150mg/l 47 82 NS NS 74 NS      
APACHE II ≥8 63 73 NS NS 71 NS    
48hrs 
 
TAP>35nmol/l 83 72 NS NS 74 NS      
CRP>150mg/l 86 61 NS NS 66 NS 
     
APACHE II ≥8 56 64 NS NS 63 NS      
Glasgow ≥ 3 75 75 NS NS 76 NS      
Ranson ≥ 3 89 64 NS NS 69 NS 
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Study Year No Timing  Endpoints Test and cut-off Sen Spec PPV NPV Accuracy AUC 
Lempinen 110 2001 150 Ad Pancreatic necrosis, 
organ failure 
U. tryp -2 dipstick 62 87 65 85 NS NS 
    
Death CRP > 150mg/l 38 90 59 79 NS NS 
     
APACHE II > 8 52 87 61 82 NS NS 
   
24 hrs 
 
U. tryp -2 dipstick 62 85 62 85 NS NS 
     
CRP > 150 mg/l 83 70 52 91 NS NS 
     
APACHE II > 8 45 86 56 80 NS NS 
Kylänpää-Bäck 
111 
2001 57 Day 0 Organ failure APACHE II ≥8 56 80 NS NS NS NS 
     
CRP>150mg/L 50 83 NS NS NS NS 
     
PCT>0.4ng/ml 69 78 NS NS NS NS 
     
sIL-2R>1000U/mL 50 78 NS NS NS NS 
   
12hrs 
 
CRP >150mg/L 56 76 NS NS NS NS 
     
PCT >0.4ng/ml 75 78 NS NS NS NS 
     
sIL-2R>1000U/mL 81 71 NS NS NS NS 
   
24hrs 
 
APACHE II ≥8 56 71 NS NS NS NS 
     
CRP ≥150mg/L 69 54 NS NS NS NS 
     
PCT >0.4ng/ml 94 73 NS NS NS NS 
     
sIL-2R>1000U/mL 81 68 NS NS NS NS 
   
48hrs 
 
Ranson≥3 88 44 NS NS NS NS 
TAP- Trypsinogen Activating Peptide 
U.Tryp- Urinary trypsinogen 
CRP - C-reactive protein 
SAPS - Simplified Acute Physiology Score  
PCT - Procalcitonin 
sIL-2R - soluble interleukin-2 receptor 
APACHE II - Acute Physiology and chronic Health evaluation 
NS: not stated  
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 Table 8b: Series of markers of disease severity in acute pancreatitis 2001-2015     
Study Year No Timing  Endpoints test and cut-off Sen Spec PPV NPV AUC 
Kylänpää-Bäck 112 2001 162 day0 Organ failure PCT-Q strip 71 84 NS NS NS 
   
day0 Mortality CRP>150mg/l 37 88 NS NS NS 
   
day0 
 
APACHE II≥8 61 82 NS NS NS 
   
day1 
 
PCT-Q strip 92 84 NS NS NS 
   
day1 
 
CRP>150mg/l 71 68 NS NS NS 
   
day1 
 
APACHE II 47 78 NS NS NS 
   
day 0 or 1 
 
PCT-Q strip 95 78 NS NS NS 
   
day 0 or 1 
 
CRP>150mg/l 74 65 NS NS NS 
   
day 0 or 1 
 
APACHE II 71 73 NS NS NS 
   
48hours 
 
Ranson≥3 45 98 NS NS NS 
Chatzicostas 113 2002 153 48hours Organ failure Ransons≥3 82 74 NS NS 0,82 
   
24hours Local complication APACHE II≥10 58 78 NS NS 0,62 
     
APACHE III≥42 56 86 NS NS 0,68 
Chatzicostas 114 2003 78 72hours Organ failure CTSI >3 76 93 89 83 0,95 
   
48hours Local complication Ranson >2 82 65 65 82 0,78 
   
24hours 
 
APACHE II >10  55 86 76 71 0,62 
   
24hours 
 
APACHE III >41 50 86 73 69 0,68 
Johnson 115 2004 186 24hours Complications APACHE II-O>8 82 86 74 91 NS 
Wu116 2008 17992 24 hours Mortality BISAP>2 NS NS NS NS 0,82 
     
APACHE II NS NS NS NS 0,83 
Koziel117 2015 944 24 hours(death) Mortality BISAP>2 NS NS NS NS 0,71 
     
Ranson≥2 NS NS NS NS 0,68 
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Study Year No Timing  Endpoints test and cut-off Sen Spec PPV NPV AUC 
     
APACHE II≥8 NS NS NS NS 0,73 
     
Panc 3≥2 NS NS NS NS 0,57 
   
24 hours (severe) Organ failure BISAP≥2 NS NS NS NS 0,69 
     
Ransons≥3 NS NS NS NS 0,63 
     
APACHE II≥8 NS NS NS NS 0,72 
     
Panc 3≥2 NS NS NS NS 0,63 
Cho 118 2015 161 48 hours Persistent organ failure Ranson≥3 86 44 19 95 0,69 
   
24 hours 
 
BISAP≥2 62 72 25 93 0,74 
   
24 hours 
 
APACHE II≥8 81 66 26 96 0,78 
   
24 hours 
 
CRP≥21.4 53 94 67 90 0,68 
   
NS 
 
CTSI≥3 67 67 23 93 0,69 
PCT-Q: Procalcitonin strip test, CRP- C-reactive protein, CTSI-Computerized Tomography Severity Index 
APACHE II-Acute Physiology and Chronic Health Evaluation, BISAP - Bedside Index of Severity 
Panc: Presence of Haematocrit (>44%), BMI(>30kg/m2) and Pleural effusion predict severe disease 
NS: not stated 
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Table 9: Parameters to calculate the SOFA score  
Parameters                                                           Score 
 0 1 2 3 4 
Respiration      
 PaO2/FIO2  >400 <400 <300 <200 <100 
 SaO2/FIO2 ? 221–     
301 
142–220 67–141 <67 
Coagulation: Platelets 
103/mm3 
>150 <150 <100 <50 <20 
Liver: Bilirubin (umol/l) <20.52 20.52–
32.49 
34.2–100.89 102.6–203.49 >205.2 
Cardiovascular: 
Hypotension 
Normotensive MAP 
<70 
Dopamine 
</=5 or 
Dopamine >5 or Dopamine >15 
or 
   Dobutamine 
(any) 
Norepinephrine 
</=0.1 
norepinephrine 
>0.1 
CNS: Glasgow Coma Score 15 13–14 10–12 6–9 <6 
      
Scores and probability of mortality 
Score   Percent  mortality   
0 - 6 <10 
7 - 9 15-20 
10 - 12 40-50 
13 - 14                                     56-60 
15   >80 
16 - 24 >90 
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Table 10: Outcomes of antimicrobial therapy RCT'S in acute pancreatitis  
Author Year Antimicrobial Concealed Blinding A P Infection RR(95% CI) Mortality RR (95%CI) 
   Allocation  A P  A P  
     Number  Number  
Pederzoli 198 1993 Imipenem Unclear No 41 33 5 10 0.40[0.15,1.06]  3 4 0.6[0.15,2.51] 
Sainio 199 1995 Cefuroxime Yes No 30 30 9 12 0.75[0.37,1.51]  1 7 0.14[0.02,1.09] 
Delcenserie 200 1996 Ceftazidime + A + M Unclear No 11 12 0 3 0.15[0.01,2.70]  1 3 0.36[0.04,3.00] 
Schwarz 201 1997 Ofloxacin + M Unclear No 13 13 8 7 1.14[0.59,2.22] 0 2 0.2[0.01,3,80] 
Nordback 202 2001 Imipenem Unclear No 25 33 1 6 0.22[0.03,1.71] 2 5 0.53[0.11,2.50] 
Spicak 203 2002 Ciprofloxacin + M Unclear No 33 30 1 0 2.74[0.12,64.69] 5 3 1.52[0.40,5.81] 
Spicak 204 2003 Meropenem Unclear No 20 21 3 6 0.53[0.15, 1.82] 4 5 0.84[0.26,2.69] 
Isenmann 205 2004 Ciprofloxacin + M Yes Yes 58 56 7 5 1.35[0.46, 4.01]  3 4 0.72[0.17,3.09] 
Røkke 206 2007 Imipenem Unclear No 36 37 3 6 0.51[0.14, 1.90]  3 4 0.77[0.19,3.20] 
Dellinger 13 2007 Meropenem Yes Yes 50 50 9 6 1.50[0.58, 3.90] 10 9 1.11[0.49,2.50] 
Barreda 207 2009 Imipenem Unclear No 24 34 3 2 2.13[0.38,11.76]  0 0 NE 
Garcia-Barrasa 208 2009 Ciprobay Yes Yes 22 19 8 8 0.86[0.40, 1.85] 4 2 1.73[0.35,8.41] 
Xue 209 2009 Imipenem Unclear No 29 27 8 10 0.74[0.35, 1.61]  3 4 0.7[0.17,2.84] 
Yang 210 2009 Imipenem Unclear No 28 26 6 8 0.70[0.18, 1.74]  2 3 0.62[0.11,3.41] 
             
Total     420 421 71 89 0.78[0.60,1.02] 41 55 0,74 
Percent       17 21  10 13  
RCT: randomized controlled trials, NE not estimable, RR: relative risk, CI: confidence interval  
M = Metronidazole A = Amikacin A = Antimicrobials  P = Placebo 
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Table 11: Patterns of mortality in series of acute pancreatitis  
Author Year Origin Number Deaths Early Late 
No % % of deaths 
Renner211 1985 USA 405 100 25 76 24 
Mann3 1994 England 631 57 9 44 56 
McKay98 1999 Scotland 13727 1030 8 54 46 
Lowham4 1999 England 105 6 6 100 0 
Mutinga212 2000 USA 805 17 2 47 53 
Ashley7 2001 USA 99 14 14 29 71 
Gloor5 2001 Switzerland 106 10 9 0 100 
Appelros6 2001 Sweden 883 21 2 62 38 
Carnovale11 2005 Italy 1150 55 5 51 49 
Frey12 2006 USA 70231 4227 6 30 70 
Mofidi9 2006 Scotland 759 45 6 51 49 
Fu213 2007 Taiwan 643 105 16 42 58 
Bai10 2007 China 1976 233 12 79 21 
Dellinger13 2007 Multicentre 100 19 19 42 58 
Bumbasirevic14 2009 Serbia 110 59 54 25 75 
Overall   76752 4746 9 43 57 
Anderson17 2008 South Africa 322 28 9 79 21 
Anderson19 2017 South Africa 627 42 7 67 33 
South Africa   949 70 8 73 27 
Total   77701 4816 9 58 42 
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Table 12: Outcomes of surgery in infected pancreatic necrosis   
Procedure                            Fistula (%)  
Open laparotomy        Year        No Infection (%) Pancreatic Enteric Total Haemorhage (%) Mortality 
(%) 
Beger214 1988 95 42 NS NS NS NS 8 
Fernandez-del Castillo 215 1998 64 56 53 16 69 5 6 
Branum216 1998 50 84 72 16 88 ns 12 
Bosscha217 1998 28 100 NS NS 25 50 39 
Raraty218 2010 52 72 8 10 18 17 38 
Pupelis219 2013 36 44 22 22 44 83 19 
Wronski220 2017 22 77 32 36 68 29 27 
Planned re-laparotomies         
Sarr221 1991 23 75 26 52 78 26 17 
Tsiotos222 1998 72 79 19 27 35 18 25 
Closed continuous lavage         
Farkas223 1996 123 100 13 1 14 2 7 
Farkas224 2006 220 100 NS NS NS NS 8 
Surgical step-up 
approach  
        
van Brunschot225 2018 47 98 32 17 49 21 13 
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Table 13: Series of minimally invasive necrosectomy reporting outcomes   
Procedure 
 
Year No Infected 
Procedure 
completed 
Sepsis ↓ Morbidity Mortality 
Percutaneous    %  
Freeny228  1998 34 100 47 74 0 12 
Echenique229  1998 20 100 100 NS 50 0 
Gouzi230  1999 32 81 65 NS 59 15 
Retroperitoneal laparostomy        
Fagniez231  1989 40 97 NS NS 50 33 
Villazon232  1991 18 100 NS NS 38 22 
Nakasaki233  1999 8 100 NS NS 65 25 
Raraty218  2010 137 64 86 NS 55 19 
Pupelis219  2013 22 64 NS 71 45 5 
Laparoscopy         
Zhu234  2001 10 0 90 NS NS 10 
Retroperiteonoscopy         
Gambiez235  1998 20 65 75  65 10 
Carter236  2000 10 100 80 NS 28 20 
Castellanos237  2002 15 100 NS NS 20 27 
Connor238  2003 24 100 87 NS 88 25 
Bakker239  2012 10 90 100 NS 90 40 
van Brunschot225  2018 47 98 100 NS 32 13 
Endoscopic         
Bakker239  2012 10 100 100 NS 10 10 
van Brunschot225  2018 51 90 100 NS 25 18 
Sepsis ↓:  % decline in sepsis
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Table 14: Accuracy of serological predictors of infected pancreatic necrosis   
Author  
   
Year  
   
Test  
   
Duration assay 
Sens  
%  
Spec  
%  
PPV  
%  
NPV  
%  
Rau140  1997  PCT (1.8 ng/ml)   1st 2 days  94 91 NS NS 
      IL-8 (112 pg/ml)       72 75 NS NS 
Riche213  2003  IL-6 (< 400 pg/l) + 
PCT (< 2 ng/l)  
1st 3 days  
   
75 84 60 91 
      
Rau141  2007  PCT≥3.5 ng/ml  1st 2 days  93 88 NS NS 
      CRP ≥430 mg/l     40 100 NS NS 
      PCT≥3.5 ng/ml  3rd and 4th day  79 93 NS NS 
      CRP ≥430 mg/l     36 97 NS NS 
PCT: Procalcitonin. IL: Interleukin, CRP: C-reactive protein, Sens: sensitivity, Spec : specificity, 
PPV : positive predictive value, NPV : negative predictive value, NS: not stated 
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Table 15: Admissions: Addington and Prince Mshiyeni Memorial hospitals showing 
numbers and ethnic distribution  
Periods 
 
Addington PMMH p-value 
 n n  
General surgery hospital admissions    
Aug 2013- July 2014 5370 12775  
Aug 2014- July 2015 5874 14141  
Aug 2015- Oct 2015 1558 4079  
Total 12802 30995  
  
 
 
Trauma admissions: n=181(%) 76(42) 105(58)  
Age:                     mean(±SD) 33(±13) 33(±11)  
Gender:               male (%)   67(88) 93(89)  
                             female (%) 9(12) 12(11)  
Ethnicity: n(%)    
                          African 62(82) 101(96) 0.0019 
                          Mixed  4(5) 1(1)  
                          White 6(8) 2(2)  
                          Indian 4(5) 1(1)  
  
 
 
Pancreatitis admissions: n(%)    161(0.01) 77(0.002)  
Age:                     mean(±SD) 40(±13) 35(±11) 0.0017 
Gender:               female (%) 64(40) 36(39)  
                             male (%)   97(60) 41(51)  
Ethnicity: n (%)    
                          African 82(51) 75(97) 0.0001 
                          Mixed  8(5) 0  
                          White 4(2) 1(1)  
                          Indian 67(42) 1(1) 0.0001 
Complications: n(%)  
 
 
                          pancreatic ascites 10(6) 7(9)  
                          pancreatic fluid collections 8(5) 8(10)  
                          portal vein thrombosis 1(1) 2(3)  
                          abscess 1(1) 3(4)  
                          pancreatic necrosis 5(3) 8(10) 0.0240 
Mortality                           6(4) 6(8) 0.0046 
PMMH = Prince Mshiyeni Memorial Hospital 
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Table 16: Patient demographics, ethnicity and HIV status  in trauma and pancreatitis 
cohorts  
 Trauma Pancreatitis   
 No  No  p-value 
Total 181  238   
Characteristic  SD  SD   
Age: mean (±SD) 33 ±11.8 40 ±12.3 <0.001 
Gender         %           %  
Female 22 12 100 42 <0.001 
Male 159 88 138 58  
Ethnicity      
African 157 87 157 66 <0.001 
Mixed 6 3 8 3  
Indian 12 7 68 29  
White 6 3 5 2  
HIV status      
1 99 55 126 53 <0.001 
2 29 16 90 38  
3 53 29 22 9 <0.001 
On HAART  17 59 53 59  
1: HIVnegative  2: Tested positive or known  3: Declined testing 
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  Table 17 General characteristics, severity markers and outcomes of the pancreatitis 
cohort  
Total  238  
Parameter  Mean SD 
Age (years)  40 ±12.3 
  No Percent  
Gender Female 100 42 
 Male 138 58 
Ethnicity African 157 66 
 Mixed 8 3 
 Indian 68 29 
 White 5 2 
Aetiology Alcohol 117 49 
  Gallstones 66 28 
  Dyslipidaemia 6 3 
  Drugs 24 10 
  Idiopathic 25 11 
CRP>150mg/l Evaluated in 213(89%) 83 39 
BISAP ≥ 2 Evaluated in 238(100%) 40 17 
Glasgow ≥ 3 Evaluation based on 9 factors in 225(95%) & 8 
factors in 13(5%) 
55 23 
APACHE 2 ≥ 8 Evaluation based on 14 factors in 233(98%) & 12 
factors:5(2%) 
105 44 
SIRS ≥ 2 Evaluation based on 5 factors in 231(97%) & 4 
factors:7(3%) 
128 54 
 CTSI Mild 12 5 
 Moderate 12 5 
 Severe 10 4 
Organ failure Transient 31(67%), persistent 15(33%) 46 19 
Local 
complications 
Ascites (32), Sepsis (20), Pseudocyst (12), Abscess 
(4), PVT (3), PN (11) 
33 14 
Mortality Early (≤14 days): 6   
 Late (>14 days): 6 12 5 
CRP: C- reactive protein, BISAP : Bedside Index of Severity in Acute Pancreatitis, SD-standard 
deviation, APACHE : Acute Physiology And Chronic Health Evaluation,  
SIRS : Systemic Inflammatory Response Syndrome, PVT: portal vein thrombosis,  
PN: pancreatic necrosis, CTSI: CT scan severity index  
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Table 18: HIV Status by age range, gender and ethnicity of the pancreatitis cohort  
 HIV Status  Total p value 
Negative  Positive  Unknown 
Age group n % n % n % n 0.002 
< 30 26 21 25 28 2 9 53  
30-49 65 52 57 63 12 55 134  
50-74 35 28 8 9 8 36 51  
Total 126 100% 90 100% 22 100% 238  
Gender            
Female 44 35 48 53 8 36 100 0.02 
Male 82 65 42 47 14 64 138  
Total 126 100% 90 100% 22 100% 238  
Ethnic            
African 63 50 84 93 10 45 157 < 0.001 
Mixed 7 6 1 1 0 0 8  
Indian 51 40 5 6 12 55 68  
White 5 4 0 0 0 0 5  
Total 126 100% 90 100% 22 100% 238  
HIV : Human immunodeficiency virus 
  
 91  
Table 19: Comparisons of the spectrum of aetiologies, comorbidities and diagnostic 
modalities in HIV+ve and HIV-ve pancreatitis cohorts  
Characteristic  HIV Status p-value 
  HIV-ve (n=126) HIV+ve (n=90) Unknown (n=22)  
  n Percent  n Percent n Percent  
Aetiology Alcohol 66 52 37 41 14 64 0.14 
 Gallstones 38 30 24 27 4 18 0.48 
 Dyslipidaemia 4 3 0 0 2 9 0,03 
 Drug related 0 0 24 27 0 0 <0.001 
 Idiopathic 18 14 4 6 2 9 0.09 
 Tumour 0 0 1 1 0 0  
Comorbidity Diabetes 18 14 3 3 3 14 0.03 
 Hypertension 28 22 7 8 5 23 0.02 
 IHD 4 3 1 1 0 0 0.64 
 Renal 2 2 1 1 0 0 1 
Diagnosis Imaging 2 2 0 0 0 0 0.32 
 Laparotomy 0 0 2 2 0 0 0.60 
  Mean ±SD Mean  ±SD Mean  ±SD   
 Amylase(n=234) 1106 968 1011 10326 1185 933 0.19 
 Lipase(n=185) 809 1345 1106 1768 802 1228 0.42 
 Urine  
Amylase (147) 
10794 20251 9124 18254 16311 24789 0.65 
SD: standard deviation; i: Pearson chi-squared (χ2) test or Fishers exact,  
HIV : Human immunodeficiency virus, IHD : ischaemic heart disease 
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Table 20 Diagnosis of acute pancreatitis utilizing amylase and lipase at ≥3 times upper 
limit and urine amylase at ≥1000 u/l.  
Parameter No       median IQR 
serum amylase 234 711 1030 
urine amylase 147 3861 6641 
Lipase 185 350 748 
 n %  
n=238: serum amylase ≥375 179 75 serum amylase 75% diagnostic 
                                         <375 55 23  
n=55: urine amylase ≥1000 33 60 urine amylase diagnostic in 
60% misdiagnosed by amylase 
                                     <1000 22 40  
n=22:      serum lipase ≥180 22 100 lipase diagnostic in all missed 
by amylases 
IQR: measured as the difference between the first and fourth quartiles 
   
 
 
Table 21: HAART regimens in HIV+ve patients in the acute pancreatitis cohort   
 CD4 mean(±SD)  
Not on HAART 298(±301) p=0.8181 
On HAART 348(±301)  
   
HAART regimens No % 
Lamivudine†, Tenofovir†, Efavirenz* 25 47 
Tenofovir†, Emtricitabine†, Efavirenz* 22 42 
Lamivudine†, Tenofovir†, Nevirapine* 6 11 
HAART: highly active antiretroviral therapy 
Nucleoside reverse transcriptase inhibitors (NRTI) † 
Non-nucleoside reverse transcriptase inhibitors (NNRTI) * 
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Table 22 Proportion of positive prognostication markers in relation to HIV status  
Characteristic Criteria HIV-ve(n=126) HIV+ve(n=90) Unknown (n=22) p-value 
  n Percent n Percent n Percent  
CRP <150 64 50 55 43 10 8 0.52 
 ≥150 47 57 29 35 8 10  
Glasgow <3 100 55 67 37 15 8 0.44 
 ≥3 26 46 23 41 7 13  
APACHE II <8 92 71 23 18 14 11 <0.001 
 ≥8 34 31 67 62 8 7  
BISAP <2 111 56 72 36 15 8 0.04 
 ≥2 15 38 18 45 7 18  
Organ failure No 104 54 73 38 15 8 0.29 
 Yes 22 48 17 37 7 15  
CT scan:   18 14 12 13 0 0 0.17 
CRP : C-reactive protein, APACHE : Acute Physiology And Chronic Health Evaluation,  
BISAP : Bedside Index of Severity in Acute Pancreatitis, CT : Computerised Tomography,  
HIV : Human Immunodeficiency Virus 
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Table 23: Acute pancreatitis outcomes in relation to the HIV status  
Parameter 
HIV Status  p-value 
HIV-ve(n=126) HIV+ve(n=90) Unknown (n=22)  
n Percent n Percent n Percent  
Local complications        
Pancreatic ascites 14 11 17 19 1 5 0.15 
Pancreaticfluid collection 7 6 5 6 0 0 0.82 
Pancreatic abscess 2 2 2 2 0 0 1 
Portal vein thrombosis 2 2 1 1 0 0 1 
Pancreatic necrosis 6 5 5 6 0 0 0.73 
Mortality 7 6 5 6 0 0 0.66 
 Mean ±SD Mean  ±SD Mean ±SD  
Hospital stay (days) 10 8 10 8 7 4 0.223 
SD: standard deviation, i: Pearson chi-squared (χ2) test or Fishers, HIV : Human 
Immunodeficiency Virus 
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 Table 24 Categorical assessment of severe disease parameters in relation to the HIV 
status  
Parameter   HIV status    p value 
HIV -ve HIV+ve Unknown          Total  
 n % n % n % n %  
Organ failure     
Yes 22 17 17 19 7 32 46 19  
No 104 83 73 81 15 68 192 81 0.3 
Total 126 100 90 100 22 100 238 100  
Local complications     
Yes 17 13 13 14 1 5 31 13  
No 109 87 77 86 21 95 207 87 0.4 
Total 126 100 90 100 22 100 238 100  
Mortality     
Yes 7 6 4 4 1 5 12 5  
No 119 94 86 96 21 95 226 95 0.8 
Total 126 100 90 100 22 100 238 100  
Severity     
Not severe 100 79 72 80 14 64 186 78  
Severe 26 21 18 20 8 36 52 22 0.3 
Total 126 100 90 100 22 100 238 100  
HIV : Human Immunodeficiency Virus 
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Table 25: Temporal relation of  sepsis site and micro-organisms to HIV status  
HIV Status  Organisms 
 Site 0 - 14days >14 days 
HIV-ve Blood Staphylococcus Aureus  
  Staphylococcus Aureus  
   Staphylococcus Aureus 
 Catheter tip Enterococcus  
 Sputum Candida Albicans  
  Pseudomonas  
  Candida Albicans  
   Enterobacter 
  Pseudomonas  
  Haemophilus  
  Candida Albicans  
 Urine Candida Albicans  
  Escherichia Coli  
   Candida Albicans 
 Ascites Staphylococcus Aureus Enterobacter 
  Candida Albicans  
HIV+ve Respiratory  Tuberculosis 
 Blood Escherichia Coli  
  Cytomegalovirus  
  Staphlococcus Aureus  
HIV : Human Immunodeficiency Virus 
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Table 26. Demographics, severity assessment and outcomes in patients with gallstone related 
pancreatitis in relation to HIV Status 
Variable  HIV-ve HIV+ve  
  No % No %  
Gender Female 26 68 22 92 0.059 
  Male 12 32 2 8   
Ethnicity African 20 53 24 100 <0.001 
  Mixed 1 3 0 0   
  Indian 15 39 0 0   
  White 2 5 0 0   
Staging CRP 18 47 6 25 0.058 
  Glasgow 12 32 7 29 0.841 
  APACHE II 7 18 19 79 <0.001 
  BISAP 5 13 5 21 0.423 
  Organ failure 6 16 5 21 0.613 
  CT scan 6 16 1 4 0.232 
  Cholangitis 8 21 7 29 0.467 
  Cholestasis 26 68 22 92 0.059 
Jaundice Jaundice 10 26 8 33 0.553 
  ERCP 4 11 10 42 0.004 
  BD stones  3 8 6 25 0.077 
Morbidity Local complications 5 5 4 17 0.725 
 Pancreatic ascites 4 4 2 8 1 
 Pancreatic fluid collections 3 3 2 8 1 
 Pancreatic abscess 1 1 1 4 1 
 Portal vein thrombosis 1 1 0 0 1 
 Pancreatic necrosis 2 2 2 8 0.637 
Mortality   2 2 2 8 0.637 
ALT: Cholestasis: Alanine transaminase, BD: bile duct, jaundice: bilirubin ≥51um/l, CRP : C-
reactive protein, APACHE: Acute physiology And Chronic Health Evaluation, BISAP : Bedside 
Index of Severity in Acute Pancreatitis, ERCP : Endoscopic Retrograde Cholagiopancreatography, 
Cholestasis: cholestasis will be defined as elevation of the cholestatic enzymes (alkaline 
phosphatase: > 121 U/L, gamma-glutamyl transferase:> 64 U/L and bilirubin >21 μmol/L), 
Cholangitis: Cholestasis + any 2 of temperature(>38˚C), white cell(>11×1012/L) count and 
tachycardia (>90 beats/minute). 
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Table 27. Spectrum of the SIRS response in HIV-ve and HIV+ve pancreatitis cohorts  
HIV Status   
 HIV-ve HIV+ve Unknown Total P value 
 n % n % n % No %  
SIRS Grade          
0 10 8 13 14 2 9 25 10  
1 39 31 36 40 9 43 85 36  
2 39 31 41 46 11 48 91 38 0,0003 
3 27 21 0 0 0 0 27 11  
4 11 9 0 0 0 0 11 5  
Total 126 100% 90 100% 22 100% 238 100%  
SIRS: Systemic Inflammatory Response Syndrome 
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Table 28: Pancreatitis severity assessment in the entire pancreatitis cohort  
Scoring System ROC 
 No AUC 95% Conf. Interval Sens Spec PPV NPV 
   Upper 
limit 
Lower 
Limit 
%(95% CI) %(95% CI) %(95% CI) 5(95% CI) 
SIRS≥2 213 0.66 0.58  0.75 77(63-87) 52(45-60) 31(23-40) 89(82-94) 
CRP≥150mg/dl 213 0.68 0.59  0.77 63(48-77) 68(60-70) 35(25-46) 87(80-92) 
BISAP≥2 213 0.74 0.66  0.82 44(30-59) 90(85-94) 56(40-72) 85(80-90) 
BISAP 2≥2 213 0.76 0.68 0.83 40(27-55) 92(87-95) 58(41-74) 85(79-90) 
Glasgow≥3 213 0.76 0.68 0.83 48(34-62) 84(78-89) 46(32-59) 85(79-90) 
Glagow 2≥3 213 0.78 0.70 0.85 44(30-59) 88(83-92) 51(36-66) 85(79-89) 
APACHE II≥8 213 0.79 0.72 0.87 79(65-89) 63(56-70) 37(28-47) 92(85-96) 
APACHE II 2≥8 213 0.79 0.71 0.86 64(49-76) 70(63-77) 37(27-48) 87(81-92) 
 
AUC 
Interpretation 
0.50-0.60 fails as discriminator 
0.61-0.70 is a poor discriminator 
0.71-0.80 is a fair discriminator 
0.81-0.90 is a good discriminator 
0.91-1 is excellent discriminator 
2: scores computed excluding age, ROC : Receiver operating characteristic,  AUC : Area under the curve, 
Sens,: sensitivity, Spec.: specificity, PPV : positive predictive value, NPV : negative predictive value, 
SIRS : Systemic Inflammatory Response Syndrome, CRP : C-preactive protein, APACHE: Acute 
physiology And Chronic Health Evaluation, BISAP : Bedside Index of Severity in Acute Pancreatitis, CI : 
confidence interval 
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Table 29 Pairwise comparison of the AUC of the Scoring systems  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scoring system SIRS CRP BISAP Glasgow BISAP 2 Glasgow 2 APACHE II  APACHE II 2 
SIRS≥2 X 0.8 0.049 0.1 0.04 0.11 0.09 0.03 
CRP≥150mg/dl  X 0.25 0.09 0.11 0.037 0.09 0.053 
BISAP≥2   X 0.83 0.86 0.82 0.63 0.31 
Glasgow≥3    X 0.87 0.92 0.75 0.36 
BISAP 2≥2     X NS NS NS 
Glasgow 2≥3      X NS NS 
APACHE II ≥8       X NS 
APACHE II 2≥8        X 
SIRS : Systemic Inflammatory Response Syndrome, CRP : C-preactive protein, APACHE: Acute physiology 
And Chronic Health Evaluation, BISAP : Bedside Index of Severity in Acute Pancreatitis 
NS = not significant  
Correlation is interpreted as 0.3 = weak, 0.5=moderate and 0.7=strong 
Highlighted are strong correlations, 2: scores computed excluding age 
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Table 30:  Severity assessment in the pancreatitis cohort patients in relation to HIV status  
Scoring System  No AUC Standard. 
Error 
95% Conf. Interval 
     Upper limit Lower limit 
CRP >150mg/ HIV-ve 110 0,75 0,05 0.66 0.85 
 HIV+ve 84 0,59 0,07 0.45 0.74 
BISAP≥2 HIV-ve 110 0,71 0,06 0.60 0.82 
 HIV+ve 84 0,74 0,07 0.61 0.88 
BISAP 2≥2 HIV-ve 110 0,72 0,05 0.62 0.83 
 HIV+ve 84 0,77 0,06 0.64 0.89 
SIRS≥2 HIV-ve 110 0,68 0,07 0.55 0.81 
 HIV+ve 84 0,69 0,07 0.56 0.82 
Glasgow≥3 HIV-ve 110 0,72 0,05 0.61 0.82 
 HIV+ve 84 0,78 0,07 0.65 0.91 
Glasgow 2≥3 HIV-ve 110 0,74 0,05 0.63 0.84 
 HIV+ve 84 0,79 0,07 0.66 0.92 
APACHE II≥8 HIV-ve 110 0,81 0,06 0.69 0.92 
 HIV+ve 84 0,88 0,04 0.80 0.95 
APACHE II 2≥8 HIV-ve 110 0,84 0,05 0.73 0.94 
 HIV+ve 84 0,89 0,03 0.83 0.96 
       
 
AUC 
Interpretation 
0.50-0.60 fails as discriminator 
0.61-0.70 is a poor discriminator 
0.71-0.80 is a fair discriminator 
0.81-0.90 is a good discriminator 
0.91-1 is excellent discriminator 
2: scores computed excluding age, ROC : Receiver operating characteristic,  AUC : Area under 
the curve, Sens,: sensitivity, Spec.: specificity, PPV : positive predictive value, NPV : negative 
predictive value, SIRS : Systemic Inflammatory Response Syndrome, CRP : C-preactive 
protein, APACHE: Acute physiology And Chronic Health Evaluation, BISAP : Bedside Index 
of Severity in Acute Pancreatitis, CI : confidence interval 
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Table 31: Patient demographics and outcomes in HIV+ve patients   
 CD4 Total p value 
 < 200 ≥200   
 No % No % No  
Age group      
< 30 6 30 14 70 20 0.1 
30-49 15 33 30 67 45  
50-74 5 71 2 29 7  
Gender      
Female 9 23 31 78 40 0.01 
Male 17 53 15 47 32  
Ethnicity      
African 25 38 41 62 66 0.5 
Mixed 0 0 1 100 1  
Indian 1 20 4 80 5  
White 0  0  0  
Length of stay      
< 7 days 10 38 16 62 26 0.3 
 7-13 days 5 24 16 76 21  
14-55 days 11 44 14 56 25  
Disease severity      
Severe 6 50 6 50 12 0.3 
Not severe 20 33 40 67 60  
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Table 32: Scoring systems and the relationship to CD4 count in HIV+ve patients with 
acute 
   
Score CD 4 <200                          CD4 > 200 
    95% CI    95% CI 
 No AUC SE lower upper No AUC SE lower upper 
SIRS≥2 26 0,51 0,16 0,20 0,82 42 0,83 0,04 0,76 0,91 
CRP≥150mg/dl 26 0,46 0,13 0,21 0,71 42 0,73 0,16 0,42 1,00 
BISAP≥2 26 0,62 0,15 0,33 0,91 42 0,90 0,05 0,79 1,00 
Glasgow≥3 26 0,83 0,08 0,68 0,98 42 0,81 0,13 0,55 1,00 
BISAP2≥2 26 0,62 0,15 0,33 0,91 42 0,90 0,05 0,79 1,00 
Glagow2≥3 26 0,88 0,07 0,75 1,00 42 0,81 0,13 0,55 1,00 
APACHE II≥8 26 0,80 0,09 0,62 0,98 42 0,87 0,06 0,76 0,98 
APACHE II2≥8 26 0,82 0,08 0,65 0,98 42 0,90 0,05 0,80 0,99 
 
AUC 
Interpretation: 
0.50-0.60 fails as discriminator 
0.61-0.70 is a poor discriminator 
0.71-0.80 is a fair discriminator 
0.81-0.90 is a good discriminator 
0.91-1 is excellent discriminator 
2: scores computed excluding age, SIRS : Systemic Inflammatory Response Syndrome, CRP : C-
preactive protein, APACHE: Acute physiology And Chronic Health Evaluation, BISAP : Bedside 
Index of Severity in Acute Pancreatitis, AUC : Area under the curve, CI : confidence interval, SE : 
standard error 
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FIGURES INTRODUCTION 
Figure 1: Immune regulation pathways in acute pancreatitis  
  
 ARDS: Adult respiratory distress sundrome  
  NK : natural killer 
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Figure 2: Factors influencing the mortality rate of acute pancreatitis over a century  
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 Figure 3: Temporal relation of diagnostic markers of HIV infection          
       
    
    
Figure 4: Age and gender distribution of HIV prevalence in KwaZulu Natal in 2012  
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RESULTS FIGURES  
 Figure 5: Age and gender distribution of HIV infection in the trauma and acute 
pancreatitis cohorts  
  
Figure 6: Severe disease in age brackets in relation to HIV status 
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Figure 7: ROC graph of scoring systems to detect severe disease in HIV-ve patients  
  
Figure 8: ROC graphs of scoring systems to detect severe disease in HIV+ve patients  
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Figure 9: ROC graph to detect severe disease in HIV +ve patients with CD4 count more 
than 200  
  
Figure 10: ROC graph to detect severe disease in HIV +ve patients with CD4 count less 
than 200  
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                                                   ANNEXURE TABLES 
Table 1: Risk category of likelihood of drug related pancreatitis 
Category Criteria Likeilihood 
Ia 
1 case report with positive re-challenge, other 
causes excluded 
Highly probable 
   
1b 
 
1 case report with positive re-challenge, other 
causes were not ruled out 
Probable 
   
II 
 
At least 4 cases reported, consistent latency in ≥ 
75% cases 
Likely 
   
III 
 
At least 2 cases reported, no consistent latency 
or re-challenge 
Less likely 
   
IV  
1 case report without re-challenge 
Least Likely  
 
Table 2: Acute pancreatitis grading using revised Atlanta criteria 
  
Grade Criteria 
Mild No organ failure or local and systemic complications 
Moderate       Organ failure resolving at 48hours after admission 
 or Local complications* 
Severe         Organ failure** persisting for more than 48hours 
 or Mortality during index admission 
Local Complications *pancreatic necrosis, pancreatic fluid collections, vascular complications, 
pancreatic abscess pancreatic ascites. 
Organ failure: ** defined by the Marshall score   
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Table 3: Criteria for the APACHE II scoring system  
1. Age < 44: 0 points  
2. Heart rate 70-109 beats per minute: 0 points 
3.Respiratory rate 12-24 breaths per minute: 0 points 
4.Mean arterial pressure 70-90 mmHg: 0 points 
5.Temperature 36-38.4 °C: 0 points 
6.Creatinine 62-115 µmol/L: 0 points  
7.Ph 7.33-7.49: 0 points 
8.Sodium 130-149 mmol/L: 0 points 
9.Potassium 3.5- 5.4 mmol/L: 0 points 
10.Haematocrit 30- 45.9: 0 points 
11.White blood cell count 3- 10.7 cells ×109: 0 points 
12.Glasgow coma score 15: 0 points 
13.PaO2(depending on FiO2) or A-a gradient Po2  
14.Chronic organ insufficiency or immuno-compromise   
 
Range of normal values are provided which do not attract points are provided 
Each factor is accorded 1 point and 8 or more points is a marker of severe disease 
 
 
 
 
 
Table 4: Criteria for the Glasgow score 
1. Age > 55 
2. Arterial partial pressure oxygen < 60mmHg 
3. White blood cell count >15 ×109 /L 
4. Serum calcium       < 2 mmol/l 
5. Blood urea nitrogen > 16 mmol/L 
6. Blood glucose     >10 mmol/L 
7. Serum Albumen < 32 g/L 
8. Lactate dehydrogenase > 600 U/L 
 
Each positive factor is  awarded 1 point and ≥ 3 points  predicts severe disease 
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Table 5: Criteria for Bedside Index for Severity in Acute Pancreatitis (BISAP) 
 
1. Urea > 9mmol/l 
2. Impaired mental status (Glasgow coma score <15) 
3. SIRS (Table 1) 
4. > 60 years of age  
5. Pleural effusion 
 
Each of the five criteria score one point and a score of greater than 2 defines severe disease.  
 
 
 
 
 
 
 
 
 
 
Table 6: Diagnostic criteria for Systemic Inflammatory Response Syndrome 
 
1. Heart Rate: >90/minute 
2. Respiratory rate: > 20/minute or PaCO2 <30 mmHg 
3. Temperature: >38°C or <36°C 
4. White cell count >12.0 × 109 /L or < 4.0 × 109 /L + >10% bands   
 
SIRS is defined by the presence of 2 or more of these clinical factors. 
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Table 4: Criteria for the APACHE O scoring system 
 
1. Age < 44: 0 points  
2. Heart rate 70-109 beats per minute: 0 points 
3.Respiratory rate 12-24 breaths per minute: 0 points 
4.Mean arterial pressure 70-90 mmHg: 0 points 
5.Temperature 36-38.4 °C: 0 points 
6.Creatinine 62-115 µmol/L: 0 points  
7.Ph 7.33-7.49: 0 points 
8.Sodium 130-149 mmol/L: 0 points 
9.Potassium 3.5- 5.4 mmol/L: 0 points 
10.Haematocrit 30- 45.9: 0 points 
11.White blood cell count 3- 10.7 cells ×109 : 0 points 
12.Glasgow coma score 15: 0 points 
13.PaO2(depending on FiO2) or A-a gradient Po2  
14.chronic organ insufficiency or Immuno-compromise   
 
Points allocated to BMI 
BMI < 26 = 0                         BMI 26 - 30  = 1                                                                                                                             
 
Range of normal values are provided which do not attract points are provided 
Each factor is awarded 1 point and 8 or more points is a marker of severe disease 
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Table 6:  Criteria for CT Severity Index (CTSI) score 
  
Pancreatic inflammation                                   Points  
  
Normal pancreas                                                         0 
Focal or diffuse enlargement of pancreas               1 
Peripancreatic inflammation                                      2 
Single acute fluid collection                                      3 
Two or more acute fluid collections                         4 
  
Pancreatic parenchymal necrosis  
  
None                                                                        0 
< 30%                                                                       2 
Between 30% - 50%                                              4 
> 50%                                                                       6 
 
The score is the sum of the scores of pancreatic inflammation and necrosis - maximum score of 10 
Mild: 0-3, Moderate 4-6, Severe 7-10   
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Annexure 7: INFORMED CONSENT FOR INCLUSION IN PANCREATITIS AND HIV 
STUDY 
 
Patient Information 
 
You have been diagnosed with pancreatitis. Gallstones and alcohol are the commonest causes. 
HIV infection may be a cause of the disease and may also determine the severity of the disease. 
We wish to find out if your attack is related to HIV infection. All information gathered will be 
regarded as confidential. Testing for HIV will benefit you as you will know your HIV status 
and you will be referred for appropriate counselling and treatment. Your HIV status will not 
affect the treatment you receive for pancreatitis. You do not have to agree to HIV testing and 
this will not effect the treatment you receive.  
 
I agree to be tested for HIV infection 
Subject 
Signed:                                                                    Date: 
 
Researcher 
Signed:                                                                     Date: 
 
Witness 
Signed:                                                                     Date: 
 
If you have any questions contact me on the following number: 0762621940    
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IMVUME YOKUBANDAKANYWA KUCWANINGO NGEGKIWANE LESANDULELA 
NGULAZA KANYE NOKUVUVUKALO KWAMANYIKWE 
 
Odokotela bathe uma bekuhlola, bathola ukhuthi amanyikwe akho avuvukele. Imbangela 
kungaba amatshe akheke esikhwameni senyongo, ukuphuza kakhulu utshwala, kanye 
negciwane lesandulelo ngculaza. Igciwane lesandulela ngculaza lona lingakwenza kudlange 
lokukufa. Ngakhoke sifuna ukwenza isiqiniseko ukuthi akulona yini igciwane lesandulela 
ngculaza elenza ugule ngaloluhlobo. Lonke ulwazi esiyoluthola luyoba imfihlo yethu nawe. 
Ukuhlolela leligciwane lesandulela ngculaza kuyokusiza nawe uzazi ukuthi ukuliphi bese 
welashwa ngendlela, efanele. 
 
Uma kutholakala ukuthi unalo igciwane, noma futhi ungenalo lokho akusho lutho ngoba indlela 
yokukwelapha ukuvuvuka kwamanyikwe iyefana. Nokho ke awuphoqelekile ukuba uhlole 
ngoba lokho akuzuphazamisa  esizokwelapha ngayo indlela. 
 
NGIYAVUMA UKUHLOLELA IGCIWANE LESANDULELA NGCULAZA. 
 
SIGNATURE:      DATE (USUKU): 
 
UMCINANINGI:      USUKU: 
SIGNATURE: 
 
UMFAKAZI:       USUKU: 
SIGNATURE: 
 
 
Uma unemibuzo shayela Kulenombolo 0762621940 
 
 
 
 
 
